Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MLSS - Milestone Scientific Receives CE Mark Approval of Pain-Free Single Tooth Anesthesia (STA(TM)) System
Jun 20, 2007 8:30:00 AM
LIVINGSTON, N.J., June 20 /PRNewswire-FirstCall/ -- Milestone Scientific, Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that it has been granted CE Mark approval for its award winning Single Tooth Anesthesia (STA(TM)) System. This approval permits the Company to begin marketing the STA System to dental professionals in European Union countries and other countries around the world that recognize the CE Mark approval process.
"We are very pleased to receive CE Mark approval for the STA System, which represents yet another key step forward in the execution of our global marketing and commercialization strategy for this novel product," stated Leonard Osser, Chairman and CEO of Milestone Scientific. "Considering key countries within the European Union will boast a near $33 billion collective market for professional dentistry services in 2008, according to the recent Barnes Report, this presents a compelling growth opportunity for Milestone and gives us more than ample customer targets to pursue as we advance STA's worldwide market penetration initiatives."
The FDA-cleared STA System, recently distinguished as a "2007 Top 100 Product" by leading industry publication Dentistry Today, is comprised of a computer-controlled drive unit and a single-use disposable handpiece/needle assembly. It provides newly-patented, real-time visual and audible feedback and verbal announcements via Milestone's patented CompuFlo(TM) with Dynamic Pressure Sensing (DPS(TM)) technology, thus taking the guesswork out of the administration of anesthetic. Specifically, the STA System enables the dental professional to precisely administer an intraligamentary injection to anesthetize a single tooth in only one or two minutes, rather than administering a mandibular block that anesthetizes an entire quadrant. The STA intraligamentary injection has an immediate onset, whereas the typical block injection can take eight to 12 minutes before a dentist can start treatment. The dental literature shows that approximately 30 percent of mandibular block injections are missed due to limitations of technique and delivery. This can add another five to ten minutes to the time a patient has to wait to be reinjected by the dentist. In addition, the STA intraligementary injection lasts as long as a traditional infiltration or mandibular block. All of this is accomplished with a technology that has been clinically proven to provide a pain-free injection. For more information, contact Milestone Scientific at (877) STA-IS4U or visit http://www.STAIS4U.com.
About Milestone Scientific, Inc.
Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(TM) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The Single Tooth Anesthesia (STA(TM)) computer-controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web site found at http://www.milesci.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report on Form 10-KSB for the year ended December 31, 2006. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
FOR MORE INFORMATION, PLEASE CONTACT:
Elite Financial Communications Group, LLC
Dodi Handy, President and CEO, or
Daniel Conway, Chief Strategist
407-585-1080 or via email at mlss@efcg.net
SOURCE Milestone Scientific, Inc.
----------------------------------------------
Dodi Handy
President and CEO
or Daniel Conway
Chief Strategist
both +1-407-585-1080
mlss@efcg.net
of Elite Financial Communications Group
LLC
for Milestone Scientific
Inc.
BDGR - Black Dragon Management to Buy Shares in the Open Market
Jun 19, 2007 3:20:00 PM
OIL CITY, LA -- (MARKETWIRE) -- 06/19/07 -- Black Dragon Resource Companies (PINKSHEETS: BDGR) management today announced that the Board of Directors has unanimously voted to take the proper measures, including buying shares in the open market to thwart a possible hostile takeover attempt.
Management believes that the recent decline in stock price is due to a group who is looking to orchestrate a hostile takeover. The recent $.05 share price has the Company valued in the mid $4 million range. Management considers this to be a ridiculously low figure, when one takes into account Black Dragon's current production.
"Black Dragon management has started to buy shares in the open market and will, if at all possible, retire 10% of outstanding shares, in order to fight off this takeover bid and get the value of the stock back where it belongs," stated Joe Lanza, CEO of Black Dragon.
About Black Dragon:
Black Dragon Resource Companies, Inc. is an oil and gas Production Company focused on the acquisition of mature, producing and existing U.S. oil and gas fields. The Company's focus on mature, domestic oil fields eliminates exploration risk, reducing costs, and provides immediate generation of income in a niche market where larger independent and major oil companies are not positioned to compete.
The statements in this press release regarding any implied or perceived benefits from existing oil and gas field properties, actual reserves and revenues to be derived from the reserves, plans to drill additional oil and gas wells, anticipated revenues, the acquisition of additional oil or gas leases, maintaining mineral lease rights, and any other such effect resulting from any of the above are forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, the continued production of gas at historical rates, costs of operations, delays, and any other difficulties related to producing minerals such as oil and gas, continued maintenance of the oil field and properties, price of oil or gas, marketing and sales of produced minerals, risks and effects of legal and administrative proceedings and governmental regulation, future financial and operational results, competition, general economic conditions, and the ability to manage continued growth.
Forward-Looking Statements
Certain information discussed in this press release may constitute forward-looking statements within the Private Securities Litigation Reform Act of 1995 and the federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions at the time made, it can give no assurance that its expectations will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to unpredictable and unanticipated risks, trends and uncertainties such as the Company's inability to accurately forecast its operating results; the Company's potential inability to achieve profitability or generate positive cash flow; the availability of financing; and other risks associated with the Company's business. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.
Contact:
UpTick.com
480-240-1700
ONCO - Oncology Med Announces That It Will Seek Listing on the NASDAQ Over The Counter Bulletin Board
Oncology Med, Inc. (PINKSHEETS: ONCO) announced today that it will seek to list and have its shares trade on the NASDAQ Over The Counter Bulletin Board. The Company will commence interviewing and engage an SEC PCBOA approved accounting firm in order to get its prior two years of financials audited in addition to broker-dealers in order to file the necessary 15C-211 paperwork. The Company expects to have its financials audited and its 15C-211 filed within the next 90-120 days and is hopeful that the listing will become effective 90 days thereafter. The Company feels that its prospects of completing potential acquisitions in addition to raising future capital will increase by following this course of action.
Dr. William J. Walker, chairman of Oncology Med, Inc., stated, "We have always planned to have our financials audited to not only provide more public disclosure and give confidence to our investors concerning the Company's performance but also as a necessary step to seek listing on the NASDAQ Over The Counter Bulletin Board. The Company has the potential of acquiring synergistic and complementary businesses within the oncology space and we believe that this is critical in moving toward accomplishing this goal."
About Oncology Med, Inc.
Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation plans to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
More information about Oncology Med, Inc. can be found at www.oncologymed.com.
NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results.
For information, please contact:
Mr. Trevor Bentley
Investor Communications
Bentley Communications
1-888-818-8738
Email Contact
Source: Market Wire (June 19, 2007 - 9:45 AM EDT)
News by QuoteMedia
www.quotemedia.com
lol
GTHA - GeneThera Enters Into Letter of Intent With Mezey Howarth Racing Stables
Jun 18, 2007 9:15:00 AM
WHEAT RIDGE, CO -- (MARKETWIRE) -- 06/18/07 -- GeneThera, Inc. (OTCBB: GTHA) announced today it has agreed with Mezey Howarth Racing Stables to provide testing for Equine Infectious Anemia (EIA). Mezey Howarth Racing Stables has agreed to guarantee GeneThera 1,000 tests for EIA at $20 per test.
GeneThera has further agreed to develop a vaccine for EIA. The letter of intent is for a $1,000,000 contract plus a percent of profits from the commercialization of the vaccine.
"EIA affects a small population of horses," said Paul Howarth, "but if one of our horses gets infected our entire stable can be affected."
"The development of the vaccine is the first of many planned agreements with GeneThera," said J. Wade Mezey. "We are expecting the testing to begin soon and the vaccine development to begin in October."
"This letter of intent and the subsequent contract is exciting for GeneThera," said Dr. Tony Milici. "It allows GeneThera to expand its current model to Equines thereby expanding the potential for GeneThera."
The vaccine development is slated to begin in October.
ABOUT GENETHERA, INC.
GeneThera, Inc. is a biotechnology company that develops molecular testing and DNA vaccines for animal diseases that may cause diseases in humans. The core of its operation is the ongoing development of molecular diagnostic assays using Real Time Fluorogenic Polymerase Chain Reaction (F-PCR) technologies to detect the presence of infectious disease from the blood of animals, particularly, live animals.
ABOUT MEZEY HOWARTH RACING STABLES, INC.:
Mezey Howarth Racing Stables, Inc. acquires, owns, manages, trains, races and ultimately syndicates thoroughbred racing prospects. The Company's strategy since inception has been to acquire and maintain a stable of race horses adequate to compete in the middle to upper echelons of the Thoroughbred horse racing industry. The primary focus of the company is on the acquisition of claimers, although horses of racing age may be acquired from time to time depending upon the then existing circumstances.
Application of the Safe Harbor of the Private Securities Litigation Reform Act of 1995:
This press release contains, and GeneThera may from time to time make, written or oral "forward-looking statements" within the meaning of the U.S. federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of uncertainties and other factors, many of which are outside GeneThera's control, that could cause actual results to differ materially from such statements. In particular, statements using words such as "may," "should," "estimate," "expect," "anticipate," "intend," "believe," "predict," "potential," or words of similar import generally involve forward-looking statements.
Contact:
GeneThera, Inc.
Dr. Tony Milici
CEO
(303) 463-6371
The Mezey Howarth Group
J. Wade Mezey/Paul Howarth
Genethera@mezeyhowarth.com
(949) 429-4007
re: IDGI
after 2 r/s float is approx 248k
(Stacy Josloff btw is (was?) married to Donny Deutsch, host of CNBC’s “The Big Idea.
just found this news...
INCA Designs, Inc. Acquires High Fashion Design Company
NEW YORK, Jun 08, 2007 (BUSINESS WIRE) -- INCA Designs, Inc. (Pink Sheets:IDGI), formerly known as Transportation Safety Technology, Inc., changed its name to INCA Designs, Inc. in April in anticipation of closing the acquisition of S2 New York Design Corp., the owner of the popular INCA line of bags, swimwear, and resort wear. In conjunction with the acquisition that closed on May 31, 2007, the Company reconstituted its Board of Directors and named new officers.
Stacy Josloff and Stephanie Hirsch serve as the Company's Board of Directors. Josloff serves as the Company's Chief Executive Officer and Chief Financial Officer and Hirsch serves as President and Secretary.
Stephanie Hirsch, a world traveler with a free spirit and creative mind, launched INCA in 1998 upon her return from hiking the Inca Trail in Peru. Inspired by the memories of her travels, she created INCA, which began as a line of handbags. After the handbags became an instant hit with Hollywood celebrities, Hirsch explored new horizons and created a line of sexy, fun swimwear and a sophisticated selection of matching cover-ups and resort wear that echoed the vibe of the INCA handbags.
Hirsch then teamed up with Stacy Josloff, who had spent ten years as a high profile sales executive at Ralph Lauren (Black and Purple Label) and Max Mara. Josloff focuses on business strategy, marketing, sales, and merchandising while Hirsch concentrates on design, public relations and production, adding new pieces to merchandise and mix and match to the collection every day.
The INCA line currently includes inca, incagirl, and inca accessories (pillows, towels, tabletop). Plans for expanding the INCA line include a boy's line (inca jr.), home accessories, 'and everything in between', says Hirsch. "We have set our sights on a new destination: full lifestyle brand development and major company expansion," says Hirsch.
Since 1998, INCA has been featured in major trend-setting magazines, including Vogue, Harper's Bazaar, Glamour, Allure, Lucky, Marie Claire, Cosmopolitan, Oprah, and Sports Illustrated Swimsuit issue (where INCA graced four pages of the special issue). INCA has been seen on national television on Good Morning America, The Oprah Winfrey Show, and MTV's House of Style. INCA is available at the best stores and specialty boutiques such as Barney's, NY; Bergdorf Goodman, NY; Scoop, NY; Fred Segal, CA; and Jill Roberts, CA.
Corporate offices are located at 53 W. 36th Street, Suite 906, New York, NY 10018. Questions should be directed to Stacy Josloff, CEO at 212-967-5212 or may be emailed to info@incagirl.com. More information about the Company is available on the Company's website at www.incagirl.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities of INCA Designs, Inc. Certain statements in this release and other written or oral statements made by or on behalf of the Company are "forward looking statements" within the meaning of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. The forward looking statements are subject to a number of risks and uncertainties including market acceptance of the Company's services and projects and the Company's continued access to capital and other risks and uncertainties. The actual results the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the date of such statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of future events, new information or otherwise.
SOURCE: INCA Designs, Inc.
CONTACT: INCA Designs, Inc., New York
Stacy Josloff, CEO, 212-967-5212
info@incagirl.com
www.incagirl.com
Copyright Business Wire 2007
funny Johno...and g'mornin
How did this not get posted...
INCA Designs, Inc. Acquires High Fashion Design Company
NEW YORK, Jun 08, 2007 (BUSINESS WIRE) -- INCA Designs, Inc. (Pink Sheets:IDGI), formerly known as Transportation Safety Technology, Inc., changed its name to INCA Designs, Inc. in April in anticipation of closing the acquisition of S2 New York Design Corp., the owner of the popular INCA line of bags, swimwear, and resort wear. In conjunction with the acquisition that closed on May 31, 2007, the Company reconstituted its Board of Directors and named new officers.
Stacy Josloff and Stephanie Hirsch serve as the Company's Board of Directors. Josloff serves as the Company's Chief Executive Officer and Chief Financial Officer and Hirsch serves as President and Secretary.
Stephanie Hirsch, a world traveler with a free spirit and creative mind, launched INCA in 1998 upon her return from hiking the Inca Trail in Peru. Inspired by the memories of her travels, she created INCA, which began as a line of handbags. After the handbags became an instant hit with Hollywood celebrities, Hirsch explored new horizons and created a line of sexy, fun swimwear and a sophisticated selection of matching cover-ups and resort wear that echoed the vibe of the INCA handbags.
Hirsch then teamed up with Stacy Josloff, who had spent ten years as a high profile sales executive at Ralph Lauren (Black and Purple Label) and Max Mara. Josloff focuses on business strategy, marketing, sales, and merchandising while Hirsch concentrates on design, public relations and production, adding new pieces to merchandise and mix and match to the collection every day.
The INCA line currently includes inca, incagirl, and inca accessories (pillows, towels, tabletop). Plans for expanding the INCA line include a boy's line (inca jr.), home accessories, 'and everything in between', says Hirsch. "We have set our sights on a new destination: full lifestyle brand development and major company expansion," says Hirsch.
Since 1998, INCA has been featured in major trend-setting magazines, including Vogue, Harper's Bazaar, Glamour, Allure, Lucky, Marie Claire, Cosmopolitan, Oprah, and Sports Illustrated Swimsuit issue (where INCA graced four pages of the special issue). INCA has been seen on national television on Good Morning America, The Oprah Winfrey Show, and MTV's House of Style. INCA is available at the best stores and specialty boutiques such as Barney's, NY; Bergdorf Goodman, NY; Scoop, NY; Fred Segal, CA; and Jill Roberts, CA.
Corporate offices are located at 53 W. 36th Street, Suite 906, New York, NY 10018. Questions should be directed to Stacy Josloff, CEO at 212-967-5212 or may be emailed to info@incagirl.com. More information about the Company is available on the Company's website at www.incagirl.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy securities of INCA Designs, Inc. Certain statements in this release and other written or oral statements made by or on behalf of the Company are "forward looking statements" within the meaning of the federal securities laws. Statements regarding future events and developments and our future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. The forward looking statements are subject to a number of risks and uncertainties including market acceptance of the Company's services and projects and the Company's continued access to capital and other risks and uncertainties. The actual results the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. These statements are based on our current expectations and speak only as of the date of such statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of future events, new information or otherwise.
SOURCE: INCA Designs, Inc.
CONTACT: INCA Designs, Inc., New York
Stacy Josloff, CEO, 212-967-5212
info@incagirl.com
www.incagirl.com
Copyright Business Wire 2007
more then you every wanted to know about....
Mercury in Retrograde ....
At 23:41 UT (Universal Time), just before midnight on June 15, 2007, Mercury, the cosmic trickster, turns retrograde in Cancer, the sign of the Crab, sending communications, travel, appointments, mail and the www into a general snarlup! It's another of those tricky time zone issues, as in places East of Greenwich (Europe; Asia; Africa; Australia; New Zealand) it happens on the 16th! This awkward period begins a few days before the actual turning point (as Mercury slows) and lasts for three weeks or so, until July 10, when the Winged Messenger reaches his direct station. At this time he halts and begins his return to direct motion through the zodiac.
Everything finally straightens out on July 24, as he passes the point where he first turned retrograde. Mercury turns retrograde three times a year, as a rule, but the effects of each period differ, according to the sign in which it happens (see box for Retrograde Periods in 2007).
A planet is described as retrograde when it appears to be moving backwards through the zodiac. According to modern science, this traditional concept arises in the illusory planetary motion created by the orbital rotation of the earth, with relation to other planets in our solar system. Planets are never actually retrograde or stationary, they just seem that way, due to this cosmic shadow-play.
Retrograde periods, although often problematic for us earthlings, are not particularly uncommon. Each planet retrogrades, except the Sun and Moon. Although a powerful astrological influence, Mercury is quite a small planet that travels at a relatively fast speed through the zodiac. Despite being the closest planet in our solar system to the Sun, it is not always in the same sign as the Sun (for example, this year Mercury turns in Cancer while the Sun is in Gemini and is still in Cancer when the Sun has moved right through Cancer and on into Leo).
Fated Events
As a rule, retrograde planets presage a period of seemingly inevitable or fated events that relate to their sphere of influence. They present us with a series of events over which we seem to have little or no control, relating especially to the sign in which the retrogradation occurs. For example, Mercury retrograde in Pisces presents quite different sets of circumstances from those generated when it retrogrades into Aquarius.
A retrograde period is best seen as a cycle, beginning when the planet begins to slow to a halt before travelling backwards through the zodiac and ending when the planet returns to the point where it first paused. However, during the cycle, the planet's energy is most powerful (and more likely to generate critical events of universal importance) when the planet makes a station: appearing motionless in the sky.
These stationary periods occur near the beginning of the cycle (when the planet first halts as it prepares to move backwards) and midway through the cycle when the retrograde planet slows to a stop before moving forward again. The "direct station" (when the planet halts before moving forward again) is the most powerful and can be used for maximum benefit.
Some astrologers consider that the "Mercury Shadow" begins some three weeks before the actual retro station (when Mercury passes the point of direct station for the first time), but I am more inclined to think that the really noticeable peculiarities begin when Mercury slows significantly, a few days before the retro station. This period of "Mercury Shadow" extends to the Return date, some three weeks after the direct station. Bear this in mind, because experience shows that the effects of the retro period are still marked during the "shadow" phase. Some of the most characteristic annoyances often occur just after Mercury makes the direct station, while he is crawling forward before picking up speed.
What does Mercury affect?
In general, Mercury rules thinking and perception, processing and disseminating information and all means of communication, commerce, education and transportation. By extension, Mercury rules people who work in these areas, especially people who work with their minds or their wits: writers and orators, commentators and critics, gossips and spin doctors, teachers, travellers, tricksters and thieves.
Mercury retrograde gives rise to personal misunderstandings; flawed, disrupted, or delayed communications, negotiations and trade; glitches and breakdowns with phones, computers, cars, buses, and trains. And all of these problems usually arise because some crucial piece of information, or component, has gone astray, or awry.
It is therefore not wise to make important decisions while Mercury is retrograde, since it is very likely that these decisions will be clouded by misinformation, poor communication and careless thinking. Mercury is all about mental clarity and the power of the mind, so when Mercury is retrograde, these intellectual characteristics tend to be less acute than usual, as the critical faculties are dimmed. Make sure you pay attention to the small print!
The Key Issue
The key issue here is one of focus. Mercury's retro phase tends to bring unforeseen changes and blockages, but the aggravation and frustration that many of us experience during these periods is often due to our own inability to roll with the punches. Is this due to our ego-fixation? Mercury sets out to restructure our thinking processes and for many of us this is painful and frustrating. Moreover, these experiences reveal flaws in our internal organisation as well as our external planning, which can make us feel foolish and inadequate.
Mercury retrograde, like any cosmic aspect, affects people differently, depending on where it hits their personal charts. Some people actually prosper under a retro Mercury, especially if Mercury is retrograde but otherwise well-aspected in their birth charts. It is also a time when matters begun under a previous retro period will come to fruition, or completion as the case may be. Firm decisions that have been previously made when Mercury is travelling normally through the zodiac may be implemented or finalised while Mercury is retrograde without too much worry, for experience shows that this can be done without undue problems arising.
Mercury Retrograde in Cancer
When Mercury is retrograde, everyone's thinking is more introspective and we tend to think about issues and concerns which relate to the sign involved. With Mercury retrograde in Cancer, people with this sign prominent in their charts will be especially prone to such introspection. There is little choice but to reconsider our personal views and opinions about life. We receive, however, an opportunity to gain insight into our own ego.
Mercury retro in Cancer creates mental and emotional confusion, combined with memory lapses. People will love praise and flattery, yet easily take offence. Home businesses are particularly susceptible to communication breakdown. Mercury in Cancer is very emotional and sensitive, so people will find it difficult to separate their thoughts from their feelings, being particularly subject to absorbing the ideas and thoughts of people in the close environment. People will seem to be much more moody than usual and emotional problems will give rise to digestive upsets. The big temptation will be to overeat to compensate for emotional disturbances.
All areas of communication are affected, especially in matters related to the family, business, particularly home business, travel, domestic relationships and real estate purchases in general. This period brings travel snafus and missed appointments of all kinds. Documents can go astray. Be sure to carry a diary and refer to it often.
lol..2 true, started the day by having no online access at all till an hour after the bell..no matter anyway..with all the MMM driving volume out of the pennies its better to take a break.
ILNS - Intellect Neurosciences, Inc. Common Stock Commences Trading Under Symbol 'ILNS'
NASD has approved quotation of Intellect's common stock on OTC Bulletin Board
Jun 14, 2007 9:35:00 AM
NEW YORK, June 14 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), a biopharmaceutical company focused on development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and related disorders, announced today that the NASD has approved the quotation of its common stock on the Over the Counter Bulletin Board under the symbol "ILNS". Trading commenced on June 13, 2007, with a closing price on that day of $2.80 per share. The Company has approximately 30 million primary outstanding shares.
"We are proud to join the ranks of publicly traded biotech companies, and are delighted to provide the investing public the opportunity to participate in our exciting journey to develop innovative solutions to Alzheimer's disease, one of today's most challenging therapeutic areas," commented Dr. Daniel Chain, Intellect's Chairman and Chief Executive Officer. "This achievement allows us to expand our financing alternatives and access the requisite capital needed to progress our ambitious clinical development plans."
"We are gratified that our shares are quoted on the OTC Bulletin Board, thus providing liquidity for investors in our common stock and providing us with additional financial flexibility," commented Intellect's President and CFO, Elliot M. Maza.
About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease. Recently, the Company successfully completed Phase I clinical trials for OXIGON(TM), a unique antioxidant and anti-amyloid compound that is a potentially disease modifying drug for Alzheimer's disease and other important medical indications. Audited data from these clinical trials, conducted in The Netherlands, is expected to be available shortly.
The Company also has broad proprietary immunotherapy platforms with patented drug candidates for both passive and active immunization against Alzheimer's disease. Its pioneering activities in the field have placed it at the forefront of the attack against this devastating disease. Intellect's patent estate contains issued and pending claims in Europe, Japan, the US and other major territories, providing a formidable strategic advantage.
About Alzheimer's disease
Alzheimer's disease, the most common form of dementia, is characterized by progressive loss of memory and cognition, ultimately leading to complete debilitation and death. A hallmark feature of Alzheimer's pathology is the presence of insoluble protein deposits known as beta-amyloid on the surface of nerve cells, which results from the toxic accumulation of soluble beta-amyloid in the brain. The effects of the disease are devastating to the patients as well as the caregivers, with significant associated health care costs. It is estimated that there are over 24 million people suffering from Alzheimer's disease in the major markets worldwide with the number projected to increase to 80 million by 2040 as the global population ages. Currently marketed drugs transiently affect some of the symptoms of the disease, but there are no drugs on the market today that slow or arrest the progression of the disease. These symptomatic drugs are projected to generate approximately $4 billion in sales by 2008, indicating both the size of the market and the demand for effective disease modifying drugs.
For additional information, please visit http://www.intellectns.com
SOURCE Intellect Neurosciences, Inc.
----------------------------------------------
Elliot Maza
President & Chief Financial Officer of Intellect Neurosciences
Inc.
+1-212-448-9300
FMGL changing symbol for some reason...its a lightly traded shell on daily list today
will be FNGL
CBPC - China Biopharma Signed LOI to Acquire All the Interest of a Chinese Regional Pharmaceutical Distribution Company
- Acquisition Would Bring $3 Million Additional Revenue in 2007
Jun 12, 2007 8:46:00 AM
PRINCETON, N.J., June 12 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced that its China operation subsidiary, Hainan CITIC Biopharmaceutical Development Co., Ltd. ("HCBP") has signed a letter of intent to acquire 100% of the interest of Beijing Tiancheng Haixin Pharmaceutical Co., Ltd. ("BTHP"), a regional distribution company headquartered in Beijing, China. The company believes that the acquisition will expand CBPC's presence in the Northern region of China with BTHP's well established distribution licenses and logistic facilities. The acquisition would also add direct distribution channels into 175 hospitals in the region. Currently, the main customers of HCBP are local Chinese CDCs. This acquisition would bring $3 million additional revenue in 2007 and $6 million in 2008 into HCBP's current revenue source.
According to the letter of intent, HCBP would use its internal available resource to complete the acquisition. "We are very happy to see this acquisition could take place," said Peter Wang, CEO of China Biopharma, Inc. "It would significantly improve our current distribution platforms and widen our product lines in the near future."
About China Biopharma Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the Company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines against influenza, hemorrhagic fever, and Japanese Encephalitis. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net .
CONTACT:
China Biopharma, Inc.
Attn.: George Ji
Tel: +1 (609) 651-8588
ir@chinabiopharma.net
www.chinabiopharma.net
Safe Harbor Statement
Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.
SOURCE China Biopharma, Inc.
----------------------------------------------
George Ji of China Biopharma
Inc.
+1-609-651-8588
ir@chinabiopharma.net
re: CTUV
was CVNE before a 3/1 f/s
last .80
As a result of the stock split, the Company now has 37,468,926 shares of common stock outstanding.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 8, 2007
Date of Report (Date of earliest event reported)
CENTRUS VENTURES INC.
(Exact name of registrant as specified in its charter)
NEVADA 000-52391 20-4178322
(State or other jurisdiction of (Commission File (IRS Employer Identification No.)
incorporation) Number)
810 Peace Portal Drive, Suite 200
Blaine, Washington 98230
(Address of principal executive offices) (Zip Code)
(360) 318-3788
Registrant's telephone number, including area code
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
____ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
____ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
____ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
____ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
--------------------------------------------------------------------------------
ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.
Effective June 8, 2007, Centrus Ventures Inc. (the "Company") amended its Articles of Incorporation in accordance with Article 78.207 of Chapter 78 of the Nevada Revised Statutes by splitting its issued and authorized capital on a 3-for-1 basis. Accordingly, the Company’s authorized capital of common stock has been increased from 100,000,000 shares to 300,000,000 shares of common stock, $0.001 par value per share, and the Company’s issued and outstanding shares were increased on a 3-for-1 basis such that each shareholder now holds three shares for each one share previously held.
As a result of the stock split, the Company now has 37,468,926 shares of common stock outstanding.
A copy of the Company’s file-stamped Certificate of Change to its authorized capital is attached as an exhibit to this report.
ITEM 7.01 REGULATION FD DISCLOSURE
NEW STOCK SYMBOL
As a result of the 3-for-1 stock split, the Company’s trading symbol has been changed to “CTUV.” effective June 8, 2007. As this is a true stock split, shareholders will need to surrender their old pre-split certificates to obtain a new certificate representing the post-split shares. Shareholders of record as of June 8, 2007 are entitled to redeem their existing share certificates for a new certificate reflecting the new number of shares. A letter of transmittal for that purpose will be sent to the Company’s shareholders.
PRIVATE PLACEMENT FINANCINGS
On June 11, 2007, the Board of Directors has approved two concurrent private placements as follows:
U.S. PRIVATE PLACEMENT
The Company’s Directors have approved a private placement offering of up to 1,000,000 shares (the “Shares”) at a price of $1.00 US per Share (the “US Offering”).
The offering will be made in the United States to persons who are accredited investors as defined in Regulation D of the Securities Act of 1933.
The Company will pay a commission of 10% to licensed brokers or investment dealers or other qualified finders (the “Brokers”) in connection with the US Offering and issue to the Brokers warrants (the “Brokers Warrants”) entitling them to purchase up to 10% of the number of Shares placed by them at a price of $1.25 US per Share for a period of two years from closing of the US Offering.
2
--------------------------------------------------------------------------------
The Company will grant piggyback registration rights in respect of the shares comprising the US Offering and the shares to be issued upon exercise of the Brokers Warrants, such registration rights to be subject to any restrictions that may be required by any underwriter of any offering in respect of which such registration rights may apply.
FOREIGN PRIVATE PLACEMENT
The Company’s Directors have also approved a concurrent private placement offering of up to 5,000,000 Shares to persons who are not “U.S. Persons” as defined in Regulation S of the Securities Act of 1933 (the “Foreign Offering”).
The Company will pay a commission of 10% to licensed brokers or investment dealers or other qualified finders (the “Brokers”) in connection with the Foreign Offering and issue to the Brokers warrants (the “Brokers Warrants”) entitling them to purchase up to 10% of the number of Shares placed by them at a price of $1.25 US per Share for a period of two years from closing of the Foreign Offering.
The Company will grant piggyback registration rights in respect of the shares comprising the Foreign Offering and the shares to be issued upon exercise of the Brokers Warrants, such registration rights to be subject to any restrictions that may be required by any underwriter of any offering in respect of which such registration rights may apply.
The proceeds of the U.S. Private Placement and the Foreign Private Placement offerings will be used to fund the Company’s proposed merger candidate Royal Mines Inc. and development and for general corporate purposes. There is no assurance that the U.S. Private Placement or the Foreign Private Placement offerings or any part of them will be completed. There is no assurance that the Company will enter into a formal merger agreement or complete a merger with Royal Mines Inc.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
Exhibit Number Description of Exhibit
3.1 Certificate of Change Pursuant to NRS 78.209 increasing the authorized capital of common stock to 300,000,000 shares, par value $0.001 per share.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
3
--------------------------------------------------------------------------------
CENTRUS VENTURES INC.
Date: June 11, 2007
By: /s/ Kevin B. Epp
KEVIN B. EPP, PRESIDENT
4
PKPTE - YFonGlobal Announces Intent to Trade on the OTC Bulletin Board
Premier Social Network Enabler, YFonGlobal, LLC, has Reached Agreement to Reverse Merge into with PacketPort.com, Inc. (NASD, OTC, PKPTE)
Jun 12, 2007 7:55:00 AM
Copyright Business Wire 2007
WASHINGTON--(BUSINESS WIRE)--
YFonGlobal,LLC, a leading social network enabler, announced the signing of a letter of intent with PacketPort.com, Inc., a Nevada corporation, that is currently a public corporation trading on the Over-The-Counter (OTC) Bulletin Board under the ticker symbol ("PKPTE"). Under the terms of the Letter of Intent, YFonGlobal will consummate, a reverse merger into PacketPort.com, Inc. that, upon completion, will result in YFonGlobal, LLC becoming a publicly traded corporation listed on the over the counter bulletin board. This is a non binding Letter of Intent that could lead to a transaction that must be endorsed by the respective boards of directors and shareholders prior to consummation. An appropriate Form 8(K) was filed with the Securities and Exchange Commission by PacketPort.com, Inc. on Friday, June 8, 2007.
Working closely with Source Capital Group (SCG) in Westport, CT, a leading middle market investment bank, YFonGlobal expects to raise between $5-10 million subject to completion of the reverse merger. YFonGlobal has over $8 million in contract backlog and seeks to build-out delivery and sales support services to meet substantial demand for this emerging category. Recent competitive wins against MySpace and FaceBook, have demonstrated strong demand for the feature-rich social network application offered by YFonGlobal, and marketed under the trade name, wyndstorm(TM).
"With access to public financial markets, we have a tremendous opportunity to grow our social network solutions. This financing is critical to continue our growth, execute our strategy, and maintain our leadership position in this space," said Marian Sabety, President and CEO of YFonGlobal. "Capital will be used to expand our sales force and meet the explosive demand posed by both domestic and global interest in our social network offerings. We will also expand our end-to-end customized social network applications for B2B and B2C online marketing programs. This transaction and related funding positions us to offer one-stop social network set-up, customization, and ongoing program management."
On June 14th, YFonGlobal is launching a 1.6 million subscriber social network for Golden Key, an association of international students seeking a private community for online collaboration. YFonGlobal beat MySpace and FaceBook in winning the contract to host this community based on meeting tailoring requirements that included security from non-members, blocking inappropriate content, controlled advertising, and free buddy-buddy calling between members. YFonGlobal hosts a proprietary business software application that provides online collaboration, integrated voice over IP (VoIP) calling services and encryption. Unlike MySpace and FaceBook, YFonGlobal allows clients to offer customized, private, and safe communities with controlled advertising, dramatically expanding the market for these applications to address privacy and security concerns.
About YFonGlobal, LLC
YFonGlobal, a Washington D.C.-based company, provides turnkey social networking solutions tightly integrated with voice-over-Internet Protocol (VoIP) network solutions for affinity marketing leaders. Using wyndstorm(TM) hosted application, clients can rapidly tailor and privately brand custom social networks by selecting from over 52 pre-built modules. wyndstorm provides search, security, click-to-call, consumer-posted content licensing, and other value-add features that provide high value collaboration and programming for private brand marketing. For more information about YFonGlobal, LLC, visit www.yfonglobal.com.
Source: YFonGlobal, LLC
----------------------------------------------
YFonGlobal
LLC
Nancy Rose Senich
703-442-0080
pr@wyndstorm.com
BVIC - Athersys Raises $65 Million in Concurrent Reverse Merger and Private Equity Offering
Jun 11, 2007 2:30:00 PM
CLEVELAND, June 11 /PRNewswire/ -- Athersys, Inc., a privately held biotechnology company, has announced that it has successfully completed a reverse merger with BTHC VI, Inc. (OTC Bulletin Board: BVIC). BTHC plans to change its name to Athersys, Inc. as soon as practical after all applicable requirements can be satisfied. In conjunction with the merger, BTHC has completed a private placement, resulting in gross proceeds of $65 million.
The merger transaction was completed by the merger of a wholly-owned subsidiary of BTHC and Athersys, with Athersys remaining as the surviving company and a wholly-owned subsidiary of BTHC. As a result of the merger, Athersys constitutes BTHC's sole business. The officers and directors of Athersys have replaced all of the officers and directors of BTHC, the company will retain all Athersys employees, and the company will maintain its principal operations in Cleveland, Ohio.
As part of the transaction, BTHC sold 13 million shares of common stock at $5.00 per share to institutional and other accredited investors. The company also issued to the investors warrants to purchase additional shares of common stock with an exercise price of $6.00 per share. Cowen and Company, LLC and National Securities Corporation acted as co-placement agents for the private placement.
Radius Ventures led the financing, with significant participation from OrbiMed Advisors, RA Capital Management, Accipiter Capital Management LLC, Hambrecht & Quist Capital Management LLC, MPM BioEquities, and Pappas Ventures, as well as a number of other well-known healthcare institutional investors. Joining the board at the closing of the transaction will be Jordan Davis, Managing Partner of Radius, Mike Sheffery, General Partner of OrbiMed, and Floyd D. Loop, M.D., Venture Partner at Radius. Proceeds from the financing will be used primarily to fund the continued clinical development of Athersys' obesity program, including its lead candidate, ATHX-105, and its non-embryonic stem cell product, MultiStem(R), to treat patients for certain cardiovascular disorders, bone marrow transplantation support, and other disease indications, certain pre-clinical development activities, debt repayment, working capital and general corporate purposes.
"We are excited to invest in Athersys in connection with its debut as a publicly-traded company," said Jordan Davis. "In particular, we are attracted to Athersys' "fast follower" approach and its focus on developing products that have "best-in-class" potential in multibillion dollar markets."
The securities issued by BTHC have not been registered under the Securities Act of 1933 or any state securities laws. Therefore, such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933 and any applicable state securities laws. This press release does not constitute an offer to purchase any securities or a solicitation of an offer to sell any securities.
About Athersys
Athersys is a biopharmaceutical and regenerative medicine company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. Through the application of its proprietary technologies, it has established a pipeline of therapeutic product development programs in multiple disease areas. Athersys' lead product candidate, ATHX-105, a highly selective agonist of the serotonin receptor 5HT2c, a validated molecular target located in the region of the brain that regulates appetite and food intake. Compounds acting on this target have been shown to reduce appetite and result in weight loss in animal models and humans. In addition to its lead product candidate, the company is developing novel pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary capabilities and technologies including Random Activation of Gene Expression (RAGE).
Athersys is developing MultiStem(R) to treat patients for certain cardiovascular disorders, stroke, bone marrow transplantation and oncology support, as well as other disease indications. MultiStem is a patented stem cell product that is based on a special class of adult-derived stem cells known as Multi-Potent Adult Progenitor Cells (MAPC). MultiStem may be isolated from the bone marrow and other non-embryonic tissue sources, can be routinely expanded to create large product inventories, and is being developed for off- the-shelf treatment of patients. Athersys is a founding member of the Center for Stem Cell and Regenerative Medicine based in Cleveland, Ohio, with the Cleveland Clinic, University Hospitals and Case Western Reserve University.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "should," "will," or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as human therapeutics, including the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues. These risks may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. Other important factors to consider in evaluating our forward-looking statements include: the possibility of delays in, adverse results of, and excessive costs of the development process; changes in external market factors; changes in our industry's overall performance; changes in our business strategy; our ability to protect our intellectual property portfolio; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; and the success of our competitors and the emergence of new competitors. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Athersys, Inc.
----------------------------------------------
William (B.J.) Lehmann
J.D.
President and Chief Operating Officer
bjlehmann@athersys.com
or Laura Campbell
Vice President of Finance
lcampbell@athersys.com
of Athersys
Inc.
+1-216-431-9900
BPMT - Value Providers Inc, the Largest Manufacturer of Durable Medical Equipment Sold in the U.S., Makes Substantial Investment Into BioPharmetics, Inc.
Investment Expected to Increase BioPharmetics Sales to Over $20 Million per Year
Jun 11, 2007 8:31:00 AM
SUN VALLEY, CA -- (MARKETWIRE) -- 06/11/07 -- BioPharmetics, Inc. (PINKSHEETS: BPMT) announced that Value Providers Inc, one of the largest manufacturers of Durable Medical Equipment sold in the U.S., has made a significant investment into BioPharmetics.
Under the terms of this investment, BioPharmetics will now become the exclusive distributor on all current and future VPI product lines to include Medicare reimbursed products such as wheelchairs, walkers, and various other home and healthcare products throughout the U.S., its territories and the United Kingdom. In addition, BioPharmetics will assume full responsibility to manage sales through a network of 500 dealers throughout the U.S.
The company issued the following statement, "Through this investment into BioPharmetics, Inc., the company now has a dealer network of over 500 throughout the U.S. with manufacturer pricing in place to assist our dealers in best pricing to deepen their market share and assist us in reaching our projected sales goals of close to $20 million over the next 12 months. In addition, as competitive bidding through Medicare is finalized over the next 5 months, we'll be in a prime position to capture a significant portion of the bids through the dealer network. This could have an impact on our revenues to potentially see the company reach close to $100 million in sales over the next 36 months," stated Mr. Paul D. Lisenby, CEO of BioPharmetics, Inc.
For dealers looking for guaranteed lowest product pricing for competitive bidding, please call 877-819-8701 XT 245
About BioPharmetics, Inc. (PINKSHEETS: BPMT) www.biopharmetics.com
BioPharmetics, Inc. provides quality durable medical equipment, diabetic supplies, and health, beauty, and anti-aging products to customers in the U.S., Canada, and over 23 countries throughout the world. The company operates three separate divisions: Biotechnology, Pharmaceuticals, and Cosmetics. The pharmaceutical division, our largest, distributes medical equipment and diabetes supplies, dispenses physician-prescribed medications through our pharmacy partners, as well as working closely with our dealer network, health care companies, and managed care facilities to provide superior pricing and customer support for Medicare, Medi-Cal, Medicaid and private insurance reimbursement programs.
Safe Harbor
This press release contains or may contain forward-looking statements such as statements regarding the Company's growth and profitability, growth strategy, liquidity and access to public markets, operating expense reduction, and trends in the industry in which the Company operates. The forward-looking statements contained in this press release are also subject to other risks and uncertainties, including those more fully described in the Company's filings with the Securities and Exchange Commission. The Company assumes no obligation to update these forward-looking statements to reflect actual results, changes in risks, uncertainties or assumptions underlying or affecting such statements, or for prospective events that may have a retroactive effect.
Contact:
FutureTechIR for BioPharmetics
Investor Relations
(727) 417-9338
Hedge funds JANA Partners and S.A.C. Capital Advisors, which control about 8.4 percent of TD Ameritrade, have told the company it should merge with either of its rivals, E*Trade Financial or Charles Schwab Corp. to boost shareholder value.
lil about...SAC Capital / Steven A. Cohen
SAC Capital Advisors in a harsh spotlight
March 27, 2006
The secretive hedge fund SAC Capital Advisors, run by Stephen Cohen, is taking some big media hits. 60 Minutes ran a lengthy piece on its battle with Biovail, which has sued the hedge fund and is more than willing to discuss the issues publicly. Its take is that SAC conspired with a so-called independent research outfit to produce damaging reports and then pushed the firm to delay release of the report so it could build a short position.
How Does Steve Cohen Do It?
Your article about "Stevie" Cohen was infuriating ("The most powerful trader on Wall Street," Cover Story, July 21). Clearly, the markets are stacked in favor of people like SAC Capital Advisors founder Steven A. Cohen, who (according to your writers) trades on special, nonpublic, material information that is unavailable to the public.
Geoffrey Batrouney
New Rochelle, N.Y.
You note that SAC Capital Advisors pays full commissions and thereby receives analysts' recommendations ahead of the general public. How is this different from one of his traders acting on information from his analyst wife before it is made public?
Ted Levin
Grant, Koehler & Levin Ltd.
Seattle
Editor's note: The writer is a partner in an investment advisory firm.
"The most powerful trader on Wall Street" did not make it clear just how effective the alleged "three aggressive tactics" have been for SAC Capital Advisors, and you neglected to mention the extent to which SAC uses the legal practice of "front-calling" (not to be confused with the illegal practice of "front-running"). I suspect that such tactics would not add more than a few basis or percentage points to long-term returns, and that most of SAC's returns have been caused by other factors.
Charlie Stromeyer Jr.
Concord, Mass.
AUGUST 11, 2003
Hedge Funds Rattle Ameritrade's Cage
By Laurie Kulikowski
TheStreet.com Staff Reporter
6/8/2007 11:47 AM EDT
Two activist hedge funds say the time for TD Ameritrade (AMTD - Cramer's Take - Stockpickr - Rating) to sell itself is now.
The funds, S.A.C. Capital Advisors and Jana Partners, have taken an 8.4% stake in the Omaha, Neb., online broker. They called Friday for the second time in a week on Ameritrade to sell itself to either Charles Schwab (SCHW - Cramer's Take - Stockpickr - Rating) or E*Trade Financial (ETFC - Cramer's Take - Stockpickr - Rating).
"Quite frankly, we fail to see how an unbiased review could leave any doubt that the 'right time' to pursue such a combination is now," the hedge funds say in a letter to Ameritrade and accompanying press release. "This is particularly true given that the company has now completed its integration of TD Waterhouse and that the currently favorable industry environment for transactions will most assuredly not last forever, creating the real risk that if the board continues to wait it will have permanently squandered this opportunity."
The comments from S.A.C. and Jana come a day after Ameritrade chief Joe Moglia told investors that the company would be "deliberate" in pursuing its growth strategy.
Shares of all three online brokers rose on the news. TD Ameritrade's stock rose 41 cents, or 2%, to $20.41. Shares of E*Trade rose 37 cents, or 1.5%, to $24.55. Schwab, which has said it's not interested in buying Ameritrade, rose 10 cents to $21.32.
S.A.C. and Jana first suggested Tuesday that TD Ameritrade "pursue a business combination with one of its industry peers."
In Friday's letter, S.A.C. and Jana also reiterated that they see "glaring conflicts of interest" in TD Ameritrade's dealings with its largest shareholder, TD Bank (TD - Cramer's Take - Stockpickr - Rating). The funds say TD Bank won't pursue a sale of Ameritrade because of "its reliance on the company to advance its own business strategy."
They suggested that TD Ameritrade use a committee of outside directors that is "free from influence" of TD Bank to review possible merger considerations.
Moglia said Thursday at a Sandler O'Neill & Partners Conference that the company regularly reviews its M&A strategy and cautioned that investors should not limit the company's next acquisition to just an online broker.
The company has "an intense focus on our business plan and along with that really looking hard to make sure we are looking at a number of opportunities in the marketplace -- not just what's going on in online brokerage," Moglia said. "As we get more into the asset gathering space perhaps we're supposed to be more creative with regard to where we might look for strategic opportunities."
POPT..popping
MAXC - Maxco, Inc. Declares Dividend of $2.00 Per Share on Its Common Stock
May 25, 2007 4:01:00 PM
GRAND LEDGE, Mich., May 25 /PRNewswire-FirstCall/ -- Maxco, Inc. (the "Company") (Pink Sheets: MAXC) has declared a cash dividend of $2.00 per share, payable June 29, 2007, to common shareholders of record as of June 20, 2007.
Maxco's President and CEO Max A. Coon, stated "Historically Maxco has not paid dividends on its common stock. Due to the cash flow from the sale of our former 100% owned subsidiary, Atmosphere Annealing, Inc., Maxco's Board felt that it would be in the best interest of Maxco's shareholders to declare this dividend."
Maxco has investments in real estate and investments representing less than majority interests in the following businesses: a developer, manufacturer and marketer of microprocessor-based process monitoring and inspection systems for use in industrial manufacturing environments; and an energy-related business.
SOURCE Maxco, Inc.
----------------------------------------------
Max A. Coon
CEO of Maxco
Inc.
+1-517-627-1734
MAXC - Maxco, Inc. Files Form 15 With Securities And Exchange Commission
Jun 8, 2007 11:12:00 AM
GRAND LEDGE, Mich., June 8 /PRNewswire-FirstCall/ -- Maxco, Inc. (the "Company") (Pink Sheets: MAXC) announced today the filing of a Form 15 with the Securities and Exchange Commission (the "SEC"). Maxco filed the Form 15 with the SEC in order to effect a termination of registration of its common stock and Series Three preferred stock under the Securities Exchange Act of 1934.
Under the SEC'S rule, a company with fewer than 300 shareholders of record may voluntarily terminate the registration of its securities by filing a Form 15 pursuant to which it certifies that the number of record holders of the class of securities registered is less than 300. Maxco currently has fewer than 300 common shareholders of record and has no Series Three preferred shareholders. Registration of the securities will not terminate until 90 days after the filing of the Form 15; however, the Company's duty to file periodic reports such as 10Qs and 10Ks is suspended immediately upon filing the Form 15. The Company's shares are quoted in the Pink Sheets quotations system.
Maxco is taking action for a number of reasons, foremost of which is the cost associated with being a SEC reporting company is substantial for a company its size, especially in light of the additional costs associated with compliance with Sarbanes Oxley. The Maxco Board of Directors believes that the high cost of Sarbanes Oxley compliance far exceeds its benefit to Maxco shareholders. Other factors considered as part of this decision were: (i) the Company's common stock is very thinly traded, (ii) the Company foresees no capital raising benefits from being a reporting company.
Max A. Coon, President and Chief Executive Officer of Maxco, Inc., stated that it is the Company's intention to provide its shareholders annual audited financial information as well as to make available unaudited quarterly financial information (copies will be sent to shareholders upon request).
Maxco has investments in real estate and investments representing less than majority interests in the following businesses: a developer, manufacturer and marketer of microprocessor-based process monitoring and inspection systems for use in industrial manufacturing environments; and an energy-related business.
SOURCE Maxco, Inc.
----------------------------------------------
Max A. Coon
CEO of Maxco
Inc.
+1-517-627-1734
CMHM - Conmed Healthcare Management, Inc. Announces Two New Service Contracts Potentially Totaling Approximately $17.1 Million
Jun 8, 2007 9:06:00 AM
Copyright Business Wire 2007
LA PLATA, Md.--(BUSINESS WIRE)--
Conmed Healthcare Management, Inc. (OTCBB:CMHM) announced the signing of two new service contracts potentially generating approximately $17.1 million in total revenue over the next five years.
The first contract with the county of Henrico, Virginia (Richmond) is to provide medical staffing services from June 1, 2007 to May 31, 2008 and may be renewed for four additional one year periods upon mutual agreement between the County and Conmed. The annual fee is approximately $2.9 million for the first full year of the agreement and $14.2 million if all of the four one year renewal periods are exercised.
The second contract with Jackson County, Oregon (Medford) is a full risk contract to provide medical staffing, pharmaceuticals, hospitalization, dentistry, and other specialty care plus related services to the county's adult detention center, the juvenile service center and community justice transition center (work release). The contract extends from May 15, 2007 to June 30, 2010 with an annual fee of approximately $0.9 million and $2.9 million for the full term of the contract.
Richard W. Turner, President and CEO of Conmed stated, "We are extremely pleased to have won both of these new contracts. The contract with the County of Henrico, Virginia is our second contract in the state and is located adjacent to the state capitol of Richmond. The county has two detention centers with an average inmate population of approximately 1,200. The Jackson County contract is our first contract in the state of Oregon and strengthens our expansion into the Pacific Northwest. The contract covers approximately 400 individuals, which includes the first juvenile service center serviced by Conmed Healthcare Management."
About Conmed
Conmed has provided correctional healthcare services since 1984, beginning in the state of Maryland, and currently services 20 detention centers and facilities at the county level throughout the United States. Conmed's services have expanded to include mental health, pharmacy and out-of-facility healthcare expenses.
Forward Looking Statements
This press release may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the company's plans, objectives, expectations and intentions; and (ii) other statements identified by words such as "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties including those contained in its public filings. Actual results may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the company's control including, without limitation, the Company's ability to increase revenue and to continue to obtain contract renewals and extensions.)
Source: Conmed Healthcare Management, Inc.
----------------------------------------------
Conmed Healthcare Management
Inc.
Thomas W. Fry
301-609-8460
Chief Financial Officer
tfry@conmed-inc.com
In addition, the Company's principal stockholder, Kevin B. Epp, would agree to surrender for cancellation to the Company 23,500,000 (post-split) shares of the Company's common stock held by him.
As a result of the proposed transactions upon completion of the proposed merger, the Company would have approximately 45,700,000 (post-split) shares of common stock issued and outstanding.
CVNE,
on daily list 3/1 f/s, also...
from recent pr...
(negotiating a possible merger)
Centrus Ventures Inc. Announces Stock Split
Wednesday May 30, 8:17 pm ET
BLAINE, WA--(MARKET WIRE)--May 30, 2007 -- Centrus Ventures Inc. (OTC BB:CVNE.OB - News) (the "Company") announced today that its director has approved a 3-for-1 stock split of its authorized and issued shares of common stock. The split is expected to be effective on June 8, 2007.
The Company also announced that it is negotiating a possible merger with Royal Mines Inc., a Nevada corporation engaged in mineral property exploration and development in Nevada and Arizona. The parties anticipate that the merger will be accomplished on a basis that will result in the existing stockholders of Royal Mines Inc. receiving approximately 31,700,000 (post-split) shares of the merged entity. In addition, the Company's principal stockholder, Kevin B. Epp, would agree to surrender for cancellation to the Company 23,500,000 (post-split) shares of the Company's common stock held by him.
As a result of the proposed transactions upon completion of the proposed merger, the Company would have approximately 45,700,000 (post-split) shares of common stock issued and outstanding. The Company has instructed its legal counsel to prepare a formal agreement for the merger. There is no assurance that a formal agreement will be executed or the merger completed.
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors including risks disclosed in the Company's periodic filings with US securities regulators. When used in this news release, the words such as "proposed," "could," "plan," "estimate," "expect," "intend," "may," "potential," "should," and similar expressions, are forward-looking statements. In particular there is no assurance that a formal merger agreement will be executed or that the proposed merger and share cancellation will be completed.
Contact:
Contact:
Carol Kinney
Centrus Ventures Inc.
Suite 200, 810 Peace Portal Drive
Blaine, WA 98230
Telephone: (360) 318-3788
--------------------------------------------------------------------------------
Source: Centrus Ventures Inc.
no..that does not make me feel any better at all.
CNTE to CNEW to DBTB fyi
AMZB - Amazon Biotech, Inc. Announces Reverse Split
Jun 4, 2007 11:03:00 AM
NEW YORK, NY -- (MARKETWIRE) -- 06/04/07 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D) ("Company") today announced that the Company has received notice from the National Association of Securities Dealers, Inc. (the "NASD") that effective at the opening of business on June 6, 2007, the Company has effected a reverse split of its outstanding voting securities on a basis of one for three.
Dr. Mechael Kanovsky, CEO of Amazon Biotech, explained, "The reverse split is a very important step to the Company's future. Besides the immediate goal of financing the impending clinical trials, Amazon Biotech is looking for additional financing for the purpose of restructuring and acquisitions to ensure that Amazon Biotech will be the leader in whole plant pharmaceuticals."
About Amazon Biotech, Inc.
Amazon Biotech, Inc. is a natural plant pharmaceutical drug company, primarily developing immunomodulator drugs. AMZ0026 is the Company's first such drug to be used for the treatment of HIV/AIDS. The Company plans on initiating Phase I/II clinical studies of AMZ0026 in the near future, with an eventual goal of partnering with a major pharmaceutical company. Amazon Biotech specializes in natural whole plant pharmaceutical drugs and is focused on bringing healthier pharmaceutical drugs to market.
Additional information on Amazon Biotech may be found at: http://www.amazonbiotech.com/.
Forward-Looking Statements
"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Amazon Biotech, to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Amazon Biotech's subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Amazon Biotech assumes no responsibility to update the information included herein for events occurring after the date hereof. Commitment to do a study does not represent that the Company has FDA approval on the protocol to start the study.
CONTACT:
LC Group
Rick Lutz
(404) 261-1196
lcgroup@mindspring.com
DBTB - Debut Broadcasting Corporation, Inc. Completes Reverse Merger
Begins Trading Under New Symbol DBTB.OB
Jun 4, 2007 11:02:00 AM
NASHVILLE, Tenn., June 4 /PRNewswire-FirstCall/ -- Debut Broadcasting Corporation, Inc. (Nasdaq: DBTB.OB), a radio broadcasting and syndication company, announced today that it has completed its reverse merger resulting in the company being publicly traded on the NASDAQ Bulletin Board with the new ticker symbol DBTB.OB.
Jim Wood, Chairman of Debut Broadcasting stated, "This listing represents another important milestone for Debut Broadcasting and its shareholders." He continued, "We are pleased to announce that broadcasting veteran Steven Ludwig has joined the Company as CEO and we expect to name two additional members of the management team in coming days."
Debut Broadcasting also announced that it has engaged Catalyst Financial Resources, headed by Marc Robins, CFA, to execute a comprehensive investor awareness campaign aimed at enhancing shareholder value and promoting the visibility of Debut Broadcasting in the financial marketplace.
About Debut Broadcasting Corporation, Inc.
Debut Broadcasting Corporation, Inc. (NASDAQ: DBTB.OB) is a Radio broadcasting company that creates unique synergies between syndicated programming and station ownership. The Company's nine-year old radio syndication company, Impact Radio networks (www.ImpactRadioNetworks.com) distributes programming and services to over 1,100 radio station affiliates in the United States and Canada, reaching over 40 million listeners nationwide each week. Debut Broadcasting is a newly public company trading under the ticker symbol DBTB.OB. For more information about the company please visit www.debutbroadcasting.com or e-mail ir@debutbroadcasting.com.
About Catalyst Financial Resources
Catalyst Financial Resources, LLC is an investor awareness firm assisting small-cap companies gain exposure in the financial community. Founded in 2002 by Marcus Robins, CFA, Catalyst Financial Resources has a proven track record of meeting the needs of both the management and shareholders of small-cap companies. Mr. Robins also founded RedChip Review in 1993 and has been a regular columnist for Forbes magazine. For more information please visit www.catalystresearch.com.
Forward-Looking Statements
This press release may be deemed to contain forward-looking information. Any forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements as to industry trends, future economic performance, anticipated profitability, anticipated revenues and expenses, and products or service line growth, may be significantly and materially impacted by certain risks and uncertainties, including, but not limited to, failure to meet operating objectives or to execute the operating plan, competition, and other economic factors. Additional risks and uncertainties are described in the Company's public filings with the Securities and Exchange Commission.
SOURCE Debut Broadcasting Corporation, Inc.
----------------------------------------------
Press
Marcus Rowe - Director of Marketing and Communications of Debut Broadcasting Corporation
+1-615-301-0001
ext. 104; or Investors
Aimee Boutcher of Catalyst Financial Resources
+1-973-239-2878
ELTK - Eltek Wins First Sizable PCB Order from a Major Foreign Military and Aerospace Conglomerate
-- Deliveries under the $700,000 order will begin in Q3 2007 and are expected to continue through 2008 with $450,000 to be supplied in the second half of 2007
Jun 4, 2007 10:35:00 AM
Copyright Business Wire 2007
PETACH-TIKVA, Israel--(BUSINESS WIRE)--
Eltek Ltd. (Nasdaq: ELTK), the leading Israeli manufacturer of advanced circuitry solutions, today announced that a major foreign military and aerospace conglomerate has placed an order for PCBs that will be used in the production of advanced mission critical military equipment. This order is valued at $730,000 and deliveries are anticipated to commence in the third quarter of 2007 with $455,000 to be supplied in the second half of 2007.
"This competitive win signifies the first sizeable order received from this valued customer, further reflecting the growing recognition that Eltek's market leading technological and highly reliable manufacturing capabilities are gaining worldwide," said Arieh Reichart, President and Chief Executive Officer of Eltek. "Furthermore, this initial order represents the first stage of a larger project potentially worth $2 million for Eltek. The customer's decision regarding the selection of the PCB supplier for the remainder of the project is expected to be taken in the near future."
Reichart added, "We are pleased with our recent successes in ramping up revenue contributions from successful customer engagements, as they reinforce our already strong position in key high-end verticals and provide us with increased marketing momentum and visibility."
About the Company
Eltek is Israel's leading manufacturer of printed circuit boards, the core circuitry of most electronic devices. It specializes in the complex high-end of PCB manufacturing, i.e., HDI, multi-layered and flex-rigid boards. Eltek's technologically advanced circuitry solutions are used in today's increasingly sophisticated and compact electronic products. The company has invested heavily in upgrading its production facilities over the past five years.
For more information, visit Eltek's World Wide Web site at www.eltekglobal.com.
Certain matters discussed in this news release are forward-looking statements that involve a number of risks and uncertainties including, but not limited to statements regarding expected results in future quarters, risks in product and technology development and rapid technological change, product demand, the impact of competitive products and pricing, market acceptance, the sales cycle, changing economic conditions and other risk factors detailed in the company's filings with the United States Securities and Exchange Commission.
Source: Eltek Ltd.
----------------------------------------------
ELTEK Ltd.
Amnon Shemer
CFO
+972-3-9395023
amnons@eltek.co.il
HPNN - HOP-ON's Skye-Phone Awarded Regional Approval
Etisalat Will Market Skye-phone(TM) in Middle East
Jun 1, 2007 3:15:00 PM
IRVINE, CA -- (MARKET WIRE) -- 06/01/07 -- HOP-ON, INC. (PINKSHEETS: HPNN) announced today the first carrier deployment of its Skye-phone(TM) product to Dubai's national telephone carrier Etisalat. The distribution approval, received last Monday, completes the first phase of Skye-phones' Global Peer Program (GPP).
Speaking at an Industry event in Internet city (IC), Dubai Mr. Mohamed Salem, chief manager of new product development, stated, "The Skye-phone service will enable Etisalat to exploit a previously underserved and untapped market in the region. The first deployment of service is expected in 3Q of this year in Dubai."
Skye-phone's unlimited market potential stems from integrated "peer-to-peer" VOIP and gaming communication offering full security. These unique features enable units to communicate free of cost and extra-territorially to global locations. Last month, HOP-ON's subsidiary, MobileGaming.eu, secured GBM as a market partner and negotiations continue pending INPI approval. Skye-phone's "peer-to-peer gaming" utility patent is expected to be approved this quarter as the company seeks development financing in foreign gaming markets. Dominique Triche, attorney with Chekhov and Legros in France, filed the patent application on behalf of the Company. Triche is certain the final approval will be presented to the public in the next few days, stating, "The patent is in process with the appropriate government agencies as required by guidelines. I can only remark the time of disclosure to commensurate with time requirements in Industrial Property application procedure." The patent application, filed in 2005, was recently acquired by MobileGaming.eu and will be securing financing to promote GPP in EU and Middle Eastern markets.
Peter Michaels, President of HOP-ON stated, "I am certain to face legal challenges in the U.S. for production of Skye-phone. The decision for immediate entry in global arenas where infrastructures require IP exclusivity for market security has allowed us to move forward with industry leaders and respected partners. Etisalat offered our company an opportunity to expand with Mobile-Gaming.eu. I am looking forward to our patent approval and the financing completion before the board meeting in July."
The next shareholder meeting, announced by private letter to all shareholders in both regions will include the financial investors of MobileGaming.eu. The meeting is scheduled for July 29, 2007, 6:00 p.m., Lafayette Hotel, Paris, France. For more information on updates of the approval, www.european-patent-office.org/epidos/conf/patlib/press/chapard
About HOP-ON, INC.
HOP-ON (PINKSHEETS: HPNN) develops and markets wireless phones and accessories as well as wireless surveillance systems. Its product line includes the next generation CDMA2000 handsets designed by its R&D team as well as GSM/GPRS handsets. HOP-ON targets its phones to both emerging market carriers and other domestic carriers and resellers needing an entry level priced phone. In addition, HOP-ON offers a line of innovative and attractively priced wireless accessories for both HOP-ON phones and other leading manufacturers as well as affordable, wireless surveillance systems. HOP-ON is also known for developing the world's first disposable cell phone. It was an IS-95 CDMA phone that was sold to consumers with prepaid airtime and included the capability to add on additional minutes. For more information, visit http://www.Hop-on.com .
About MN1.com
Market News First is an online, market news provider that brings investors current news on the market. Market News First is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.
Through daily, live interviews, we bring you up to date on all the established companies and inform the investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.
CONTACTS:
HOP-ON, INC.
(949) 756-9008
Danny Coleman
Market News First
Tim Bradford
(214)461-3400
Shaking my head
PhoneBrasil Intl., Inc. Announces Details on President and CEO Anderson Alves Dias
Jun 1, 2007 2:56:00 PM
Copyright Business Wire 2007
MIAMI--(BUSINESS WIRE)--
PhoneBrasil International, Inc. (Pink Sheets:PHBR) today released details on new CEO and President, Anderson Alves Dias.
In 1999, Anderson Dias initiated his activities in the telecommunications market when he founded "PhoneBrasil Inc." Instantly, Anderson Alves Dias became a partner to the cellular giant Audiovox, who was seeking representation in South America. For over two years, Audiovox had attempted, with little success, to enter and saturate the Brazilian market.
Through his well developed relationships and ties with Brazilian businesses, and more importantly, the governing parties, he was able to secure in less than two months all the necessary licenses and certificates of all the products Audiovox was to use in its endeavor via the technology company ANATEL, who is telephony market regulator in Brazil, similar to the FCC in the United States. As 01/12/2000, he began a campaign and launch of AUDIOVOX with a public presentation to the larger telecommunication conglomerates, such as Telefonica, Tim Cellular, Sercontel, Global Telecom, TELESP, as well as government officials and the president of ANATEL. Over time, as Mr. Dias' efforts were not receiving the full support of AUDIOVOX, he chose to end his representation of this company in Brazil.
To view authorization from Audiovox 2000 click here http://00ec925.netsolhost.com/5_Aud.jpg.
To view a newspaper release of Audiovox 2000 with PhoneBrasil and Anderson Dias click here http://00ec925.netsolhost.com/newsdia_12_de_Jan_de_2000.jpg.
Anderson Dias, CEO of PhoneBrasil, stated, "To be clear of our capabilities, we would like to explain the Audiovox case. Our work was to introduce, and after this, represent, AUDIOVOX in the Cellular area in Brazil with our technology. We accomplished the constitution of the PhoneBrasil (PhoneBrasil) in Brazil, in Curitiba - Pr."
"We promoted the release in Brazil, in an extremely short time, being about 25 days among Audiovox Communication's approval. January 12, 2000, receiving the main operators at that time (Telefonica Rio, Telefonica Sao Paulo, Telefonica Bahia, Tim Sul (Telecom Italia Mobile), Tim Nordeste, Americel, BCP (Bell South), Sercomtel, Telemig, TCO Cellular, among other)."
"Certification via ANATEL was completed on 9 different models in 35 days. Concluded all certification process at TIM (Telecom Italia Mobile) Sul and TIM Nordeste, Maxitel, Telefonica Sao Paulo, Telefonica Rio, Telefonica Bahia, BCP (Bell South), Tim Sul. We were invited to join with a Brazilian Treasury Department team to help them to elaborate a new Brazilian index table for cellular devices, like consultants. With our vast experience in this area, we believe that we will have full success in the markets that we are disposing ourselves to enter."
Now, Anderson Dias, CEO of PhoneBrasil, is continuing his activities in this market after many offers from large communication conglomerates and State Governments to continue what they had started. In September of 2006, Mr. Dias organized PhoneBrasil Telephony Voip Digital Inc. This company, residing in the State of Florida, has reached an agreement and has an open order with the Government of Brazil for the activation of up to 1,000,000 lines in 18 months.
This company's recent return to the VOIP market has been made through strategic partnerships with partners that dominate technological aspects like software, billing, supply, etc. for new VOIP industry.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as PHBR or its management "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
Source: PhoneBrasil International, Inc.
----------------------------------------------
PhoneBrasil International
Inc.
Miami
Anderson Alves Dias
CEO
Dennis Curtis
Advisor
754-366-2171
http://www.phonebrasil.com.br/
http://www.brasil-telecom.com/
utzeir@yahoo.com
EMXC - eMax Holdings Corporation Updates Their Current Progress
Jun 1, 2007 2:32:00 PM
SPRINGFIELD, TN -- (MARKET WIRE) -- 06/01/07 -- eMax Holdings Corporation (PINKSHEETS: EMXC), www.emaxcorp.com, today releases an update of their progress. The CEO, Roxanna Weber, stated, we have just begun to implement our plan to consolidate numerous company interests and assets which will allow the company to do several things:
1. Streamline and focus company operation activities into four surviving subsidiary companies: EMAX Technologies, EMAX Media, EMAX Networks and the Gold Rush Network
2. Contain cost with less redundant corporate office expenses
3. Preparing all filing materials for the SEC, and NASDAQ
4. Become a full reporting public company
5. Distribute several stock dividends to our loyal shareholders
CEO, Roxanna Weber stated, "It is very frustrating for us at eMax to know all the facts and details about the changes going on at eMax Holdings Corporation and then have to watch the daily trading price per EMXC share to be currently trading at a small fraction of its current book value per share. As the company has been very busy preparing all the necessary administrative affairs surrounding the company's new events, a small amount of people in the trading community have been trying to make the company stock price look weak and have been trying to hurt the company's market cap for no apparent reason. eMax is making some prudent consolidation efforts currently and all of their efforts should also correct any and all deficiencies.
"We realize that the process by our company to issue dividends has taken longer than we expected However, as we review the actual dividends that we are currently issuing, we know our shareholders will be extremely happy with their total return on investment on each share they have acquired in EMXC.
"We want to take this time to answer some questions that we received daily at our office. First we want each shareholder to know how much we appreciate each and every one of your capital and time investments. The dividends are currently being prepared for delivery to you with the help of our transfer agent.
"Below you will find information on all dividends for which you may be eligible and that the company is preparing at this time."
Older Dividend Events
1. On March 18, 2003 one in Freedom for nine shares held in eMax shares as first dividend
As originally stated and as of the record date of March 18, 2003, the first dividend is being paid to those shareholders that held shares in eMax at that time. Each shareholder as of the record date will receive one share of the new company's stock for every 9 shares of eMax they hold as of the record date, March 18, 2003.
2. On March 18, 2005, Second Dividend 1 share for each 3 shares of stock held in EMXC
The second stock dividend in eMax Alive Worldwide, Inc. is to be paid to current EMXC shareholders of record as of March 18, 2005. The resulting dividend rate is one eMax Alive Worldwide, Inc. share for every 3 EMXC shares held.
Current Dividend Matters
New Dividends
1. On April 18, 2007 eMax Holdings Corporation announced they have entered into an agreement to acquire Artists Innovations, Inc. eMax Holdings Corporation signed an acquisition agreement to acquire all assets and rights held by Artist Innovations, Inc. eMax Holdings shareholders will gain a new share of stock dividend in eMax Holdings Corporation to be issued to them for each two shares they held in eMax Holdings Corporation and with the record date May 15, 2007. The transactional value equated to EMXC shares are being valued at $.015/share.
2. On May 22, 2007 eMax Holdings Corporation announced they have signed a merger agreement with Gold Rush Investments Corp. Roxanna Weber, CEO of eMax Holdings Corporation, stated that this is the beginning of several new events that will help to consolidate company holdings and operating divisions. eMax Holdings shareholders can expect to receive a new share of stock in eMax Holdings Corporation for each four shares they hold in eMax Holdings Corporation. As of the record date of June 15, 2007. The transactional value equated to EMXC dividend shares are being conservatively valued at $.015/share.
eMax is releasing an updated shareholder letter that will fully discuss the upcoming shareholder dividend events and terms and also the previous dividends currently being issued and what they currently mean to each shareholder. Look for all current update info at our website, www.emaxcorp.com.
If you are a shareholder and do not know if we have your correct mailing address, please email us at info@emaxcorp.com your correct information.
All dividend shares will be sent directly to the shareholder at their address of record on file by mail. All shareholders who hold their shares in a brokerage account will receive their share dividends by way of their brokerage firm. The company is currently working on getting the dividends moved to the shareholders at this time. Any questions regarding these matters please feel free to call the company at 866-585-2065. We receive many emails daily and this communication does help the company keep current mailing info on file for al of our shareholders.
If you have older shares in the name of Gateways To Space, eMax Corp, or Space Wiff, you may forward them to the transfer agent at 1511 S 100 East, Suite B, Salt lake City, Utah 84105 (801-485-7978). The fee is $20.00 to exchange shares for a current certificate, and an additional fee is charged if you ask for restricted legends to be removed from shares.
About eMax Holdings Corporation
eMax Holdings Corporation (http://www.emaxcorp.com) is a diversified holding company investing in multimedia, entertainment, communication, broadcasting, IT, artificial intelligence technologies, energy and finance industries.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including, without limitation, the future press releases of eMax.
Contact:
eMax Holdings Corp.
Roxanna Weber
866-585-2065
info@emaxcorp.com
http://www.emaxcorp.com
http://www.goldrushnetwork.com
PACT - PacificNet Files 10Q Quarterly Report for Q1 2007 - First Profitable Quarter as a Gaming Technology Company
- Company reports turnaround and first profitable quarter since venturing into gaming technology business
Jun 1, 2007 12:38:00 PM
BEIJING, June 1 /Xinhua-PRNewswire/ -- PacificNet Inc. (Nasdaq: PACT), a leading provider of gaming and mobile game technology, e-commerce, and Customer Relationship Management (CRM) in China, announced today that it has filed its Form 10-Q quarterly report for First Quarter 2007 with the SEC. This report may be viewed at the SEC web site at: http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000815017
"We are happy to announce to our shareholders the filing of our 10Q for Q1 2007," said Daniel Lui, CFO of PacificNet. "It is our hope that this first look into our new gaming technology focus will give people valuable insight as to where we are going and get people excited about the prospects for our future. This filing demonstrates our progress in trying to resolve delinquent regulatory filings. I would like to convey to our shareholders that we are working very hard on the re-audit issues still pending with our 2004 and 2005 SEC filings and that we will keep our investors informed via press releases as progress is made. In the meantime, our current gaming business is strong and we invite our shareholders to come visit us in person when they visit Macau. The most compelling case for our company right now is seeing our games in action."
Overview of First Quarter Financial Results (Unaudited, in US Dollars)
-- Quarterly revenue of $9,267,000 represented an increase of 38.9% as
compared to $6,672,000 from Q1 2006. Approximately 19% of the total
revenues were generated from our new gaming technology division.
-- Quarterly gross profit was $2,539,000, an increase of 87.8% as compared
to $1,352,000 from Q1 2006. Gross margin was 27.4% for Q1 2007 as
compared to 20.3% for the same period in 2006. Our shift to gaming
technology has improved our gross profit margin. Approximately 38% of
the gross profit was generated from our new gaming technology division.
-- Quarterly operating profit was $800,000, an increase of 1,190.3% as
compare to $62,000 from Q1 2006. Operating profit margin increased to
8.6% for Q1 2007 from 0.9% for Q1 2006. We are encouraged by the
increasing profit margin coming from the new gaming technology
division. Approximately 83% of the operating profit was generated from
our new gaming technology division.
-- Quarterly net profit of $308,000, or EPS of $0.03 per basic share (or
$0.03 per diluted share), with the majority (over 80%) of the profit
coming from the new gaming technology division.
-- Cash and cash equivalents were $4,041,000 at March 31, 2007, compared
to $1,900,000 as of December 31, 2006, due to sales profits and fund
raising in the gaming technology division during the quarter.
-- Equity per share of $1.44 and cash per share of $0.34 as of March 31,
2007.
-- Quarterly revenues of $3,963,000, $527,000, and $4,773,000; and
operating profit of $400,000, ($3,000), and $1,196,000 were generated
from the Company's three business units: (1) CRM Outsourcing Services,
(2) Value Added Services (VAS) and (3) Gaming and Telecom Products,
respectively. The Company plans to restructure and simplify its
business units due to the recent sale of Guangzhou3G in the VAS
business.
-- As disclosed in the Company's 10K, the Company has taken certain
restructuring steps to provide the necessary capital to continue its
operations. These steps have included, but are not limited to: (1)
accelerating the disposal and/or spin-off of unprofitable or
unfavorable return-on-investment legacy gaming operations, which
included the sale of the Company's interest in Guangzhou3G for US$6
million during the first quarter of 2007, and entering into a sale and
purchase agreement, during the second quarter of 2007, to dispose of
certain real estate in Hong Kong for approximately US$1 million; (2)
focusing on executing the Company's new high potential gaming business
initiatives; (3) acquiring profitable and/or strategic operations
through the issuance of equity instruments; (4) forming strategic
relationships with key gaming operators in Asia; and (5) issuing and/or
restructuring the Company's currently outstanding long-term convertible
debentures.
2007 Business Outlook
Traditionally, the first quarter from January to March is a low season for our operations in China and Macau due to the long Lunar New Year holidays. Today, the Company announced the following estimates:
* The Company expects Q2 revenues will continue to grow, especially in the gaming technology division.
* The Company expects Q2 net income will continue to grow, due to delivery of gaming machines and collection of account receivables.
* PacificNet's strategy in 2007 is to streamline our operation, downsize the non-performing legacy operations, and simplify our business strategy with an emphasis on our new focus on gaming technology development.
* The Company expects a turnaround return to profitability in 2007, with positive net income and EBITDA. The Company plans to provide an updated guidance for 2007 in a few weeks.
"We are delighted to report our turnaround and first profitable quarter since our venture into the gaming technology business. As we announced during the last two earnings conference calls, we have initiated a rapid business transformation away from our low-margin telecom business and into the new high-margin gaming business," said Tony Tong, Chairman and CEO of PacificNet. "Our goal is to streamline our operation, downsize the non-performing legacy operations, and simplify our business strategy with an emphasis on our new focus on gaming technology development. In recent board and management meetings, we evaluated the early success of our gaming technology operation and were satisfied with the progress and financial performance. Our board of directors and management team has approved our new strategy to focus on the rapidly growing gaming market in greater China, Macau, and Asia, and we are seeing encouraging results beginning in 2007. With the help of professional financial advisors and bankers, we will continue to seek strategic alternatives for our low-margin telecom business units which may include sales, disposition, spin-offs and mergers. We expect our gaming revenues and profit will continue to grow throughout the rest of the year."
Daniel Lui, CFO of PacificNet, said, "I am glad to see our turnaround strategy is beginning to show profits as our venture into gaming technology has resulted in our first profitable quarter in the gaming technology business. The software expertise of the legacy software development outsourcing businesses with CMM Level 3 Certification has provided a solid foundation for the Company's bold venture into the high potential gaming technology provider business. As our continuous effort to improve our accounting and reporting workflow, I am dedicated to continue to strengthen our accounting and internal control team, and in implementation of SOX compliance procedures."
"As we have previously announced publicly, we have initiated a rapid business transformation away from the low-margin telecom business and into the new high-margin gaming business," said Victor Tong, President of PacificNet. "The recent strong sales order pipeline for our gaming technology division (PacificNet Games and Take1) is an indication of our fast shift into the expanding gaming machine business."
As mentioned in some of the recent research reports on Macau's gaming industry, PacificNet has demonstrated significant progress as a leading provider of multi-player electronic table games while in Macau, receiving very strong play levels. Addressing the need for multi-station electronic table games, such as sic-bo dice, fish-prawn-crab, baccarat, roulette and other Asian traditional table games, we have released a series of multi-player electronic gaming machines, a hybrid sic-bo and baccarat gaming device that allows a player to make bets at an electronic terminal, while viewing a live dealer turn the cards or dice by TV monitor as well as at the machine. We are satisfied with our success entrance in the highly competitive gaming technology supplier market and we believe our recently launched Asian gaming machines have demonstrated a fairly quick payback for our customers who are the legal gaming operators and casino owners. We believe we are one of the only electronic gaming providers actually based in Macau gives us a competitive advantage both on the R&D side, knowing what Asian gamers want, and the sales and service side. Our machines are specifically targeted towards the Asian market and towards Asian gamers. We have found that Western games such as reel slots, poker and blackjack popular in many other markets are not as popular in Asian markets. Several analysts who recently visited Macau have noted that customer play time on our machines vs. our competitors has been exceptional.
During the recent NASDAQ Hearing attend by PacificNet and the NASDAQ Hearing Panel in May, the management presented a plan to regain compliance with NASDAQ listing rules. The plan to the NASDAQ Hearing Panel included seeking a 3-month time frame to allow the Company to work with its new auditor to conduct a re-audit for the Company's financial reports for fiscal year 2004 and 2005 audits. The NASDAQ Hearing Panel will notify us soon about their decision.
About PacificNet
PacificNet, Inc. (http://www.PacificNet.com) is a leading provider of gaming and mobile game technology, e-commerce, and Customer Relationship Management (CRM) in China. PacificNet's gaming products are specially designed for Chinese and Asian gamers with focus on integrating localized Chinese and Asian themes and content, advanced graphics, digital sound effects and popular domestic music, with secondary bonus games and jackpots. PacificNet gaming products include: Multi-player Electronic Table Games - Baccarat, Sicbo, Fish- Prawn-Crab, and Roulette machines, Server-Based Games (SBG) with multiple client betting stations, slot and bingo machines, Video Lottery Terminals (VLTs), Amusement With Prizes (AWP) machines, gaming cabinet and client/server system designs, online i-gaming software design, and multimedia entertainment kiosks. PacificNet's gaming clients include the leading hotels, casinos, and gaming operators in Macau, Asia, and Europe, while e-commerce and CRM clients include the leading telecom companies, banks, insurance, travel, marketing and business services companies and telecom consumers in Greater China such as China Telecom, China Mobile, Unicom, PCCW, Hutchison Telecom, Bell24, Motorola, Nokia, SONY, TCL, Huawei, American Express, Citibank, HSBC, Bank of China, Bank of East Asia, DBS, TNT, China and Hong Kong government. PacificNet employs about 1,200 staff in its various subsidiaries throughout China with offices in Hong Kong, Beijing, Shanghai, Shenzhen, Guangzhou, Macau and Zhuhai China, USA, and the Philippines.
Gaming Products:
PacificNet's gaming products are specially designed for Chinese and Asian gamers with focus on integrating localized Chinese and Asian themes and content, advanced graphics, digital sound effects and popular domestic music, with secondary bonus games and jackpots. PacificNet's gaming products include:
-- Multi-player Electronic Table Games: Baccarat, Sicbo, Fish-Prawn-Crab,
and Roulette Machines, server based games (SBG) with multiple client
betting stations.
-- Slot Machines
-- Bingo and Keno Machines
-- Video Lottery Terminals (VLTs)
-- Server-Based Gaming Machines (SBG)
-- Amusement with Prizes (AWP) Machines
-- Online i-Gaming Software Development
-- Client-Server Gaming Systems
-- CMM Level 3 Certified Gaming Software Development Center in China with
200 Professional Software Developers
-- Gaming Systems, Cabinet Design and Sales, Parts Sales, OEM Games. We
design and sell gaming machine cabinets, replacement parts.
PacificNet's Business Units:
1. Gaming Technology: Electronic Gaming Machines, Mobile Games, i-Gaming
Software.
2. Legacy Business: CRM, E-commerce and Telecom Products
PacificNet's Major Operation Subsidiaries:
-- PacificNet Games Limited (PacGames), is a leading provider of Asian
multi-player electronic gaming machines, gaming technology solutions,
gaming related maintenance, IT and distribution services for the
leading hotel, casino and slot hall operators based in Macau, China and
other Asian gaming markets.
-- Take1 Technologies (http://www.take1technologies.com), is in the
business of designing and manufacturing electronic multimedia
entertainment kiosks, coin-op kiosks and machines, Electronic Gaming
Machines (EGM), bingo and slot machines, AWP (Amusements With Prizes)
games, server-based downloadable games systems, and Video Lottery
Terminals (VLT) such as Keno and Bingo machines, including hardware,
software, and cabinets.
-- Pacific Solutions Technology, is a CMM Level 3 certified software
development center with over 200 software programmers located in
Shenzhen, China, and specializes in the development of client-server
systems, internet e-commerce software, online and casino gaming systems
and slot machines, as well as banking and telecom applications using
Microsoft Visual C++, Java, and other rapid application development
tools.
-- PacificNet Epro (http://www.EproTel.com.hk): CRM Call Center and
Customer Services Outsourcing
-- PacificNet Clickcom (http://www.clickcom.com.cn), MOABC.com : VAS,SP,
(SMS, WAP)
-- Guangzhou Wanrong (http://www.my2388.com): VAS, SP, (SMS,MMS,IVR,WAP,
Java Games)
-- PacificNet Communications Limited, iMobile, (http://www.imobile.com.cn,
http://www.18900.com, http://wap.17wap.com)
Gaming Market Overview on Macau, China
As of the end of 2006, Macau (a Special Administrative Region of the People's Republic of China) has become the largest and fastest-growing gaming market in the world, and has surpassed the Las Vegas Strip in total revenues. According to statistics provided by Macau government, in 2006, Macau's gaming revenues exceeded US$7 billion (MOP 56.2 billion patacas), surpassing the Las Vegas Strip gaming revenues of US$6.6 billion. Macau borders Zhuhai City of Guangdong Province of China, one of the country's wealthiest and most developed regions and is an hour away from Hong Kong via ferry. In 2006, the number of tourists visiting Macau reached an all-time record of 22 million, an increase of 17 percent compared with 2005, of which 55%, or 12 million visitors, were from mainland China. At the end of 2006, there were 22 casinos, 83 hotels and similar establishments in Macau with close to 13,000 rooms. By 2010, the number of tourists is expected to nearly double to almost 30 million visitors per year. Approximately one billion people live within a three-hour flight of Macau. Numerous hotel, gaming, and other projects are in the works in Macau which are expected to add over 10,000 guest rooms and over 20,000 live entertainment seats in eight separate venues. The number of hotel-casinos in operation and in development in Macau continues to grow, including well- known Chinese names such as Galaxy and Melco, and famous Las Vegas names such as the Sands, the Venetian, Wynn Resort and Crown Macau. With the disposable income of the average Chinese on the rise, Macau's gaming and entertainment market is expected to grow for years to come. Macau is the only area in China where gambling is legal.
Safe Harbor Statement
This Company's announcement contains forward-looking statements. We may also make written or oral forward-looking statements in our periodic reports to the SEC on Forms 10-K, 10-Q, 8-K, etc., in our annual report to shareholders, in our proxy statements, in press releases and other written materials and in oral statements made by our officers, directors or employees to third parties. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. These statements are based on current plans, estimates and projections, and therefore you should not place undue reliance on them. Forward-looking statements involve inherent risks and uncertainties. We caution you that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Potential risks and uncertainties include, but are not limited to, PacificNet's historical and possible future losses, limited operating history, uncertain regulatory landscape in China, and fluctuations in quarterly and annual operating results. Further information regarding these and other risks is included in PacificNet's Form 10K and other filings with the SEC.
Contact:
PacificNet USA office:
Jacob Lakhany, Tel: +1-605-229-6678
PacificNet Beijing office:
Ada Yu, Tel: +86 (10) 59225000
23rd Floor, Building A, TimeCourt, No.6 Shuguang Xili, Chaoyang District,
Beijing, China 100028
PacificNet Shenzhen Office:
Tel: +86 (10) 33222088
Room 4203, JinZhongHuan Business Center, Futian District, Shenzhen, China
518040
PacificNet Macau office:
Tel: +853 28704154
Unit A-C, 12th Floor, Edificio Commercial I Tak, No. 126, Rua Da Pequim,
Macau, China.
SOURCE PacificNet, Inc.
----------------------------------------------
PacificNet USA office
Jacob Lakhany
Tel: +1-605-229-6678; PacificNet Beijing office
Ada Yu
Tel: +86 (10) 59225000; PacificNet Shenzhen Office
Tel: +86 (10) 33222088
PacificNet Macau office: Tel: +853 28704154
re: ACEN...
was over a buck when this news was posted
(teach them I guess...now .31)
ACEN - AC Energy, Potential Victim of Naked Short
May 16, 2007 1:30:00 PM
GARDNERVILLE, NV -- (MARKET WIRE) -- 05/16/07 -- AC Energy (PINKSHEETS: ACEN) addresses the recent volatility in the markets to assure their shareholders that there is no reason for a sudden decrease in price. The company has been notified that they recently been added to Regulation SHO threshold List (http://www.nasdaqtrader.com/aspx/regsho.aspx) which means that there are aggregate fails to deliver at a registered clearing agency of 10,000 shares or more per security which leads the company to believe that they are the potential victims of a Naked Short.
As defined in Rule 203(c)(6) of Regulation SHO, a "threshold security" is any equity security of any issuer that is registered under Section 12 of the Exchange Act, or that is required to file reports under Section 15(d) of the Exchange Act (commonly referred to as reporting securities), where, for five consecutive settlement days:
-- There are aggregate fails to deliver at a registered clearing agency
of 10,000 shares or more per security; and the reported last sale during
normal market hours would value the aggregate fail to deliver position at
$50,000 or more (Rule 32101 Subject to the requirements of NASD Rule 3210)
-- The level of fails is equal to at least one-half of one percent of the
issuer's total shares outstanding; and
-- The security is included on a list published by a self-regulatory
organization (SRO).
A security ceases to be a threshold security if it does not exceed the specified level of fails for five consecutive settlement days. When this occurs, the security becomes subject to mandatory close-out requirements outlined in NASD Rule 3210.
President and Director Mike Dillon states, "The company is in a great position; we have had many inquires in regards to our technology. The company is moving forward to secure more contracts and licensing agreements. The company has engaged Evans & Evans to ensure the company will continue in a profitable position." I invite everyone to view our website www.acenergyinc.com and learn more about the technology and AC Energy.
About AC Energy Inc.
AC Energy is committed to leading the world in research and development of high-quality alternative power sources for cell phones and other small electronics. Our objective is to revolutionize the battery industry by providing consumers with products of unparalleled convenience and efficiency. Through the establishment of select strategic partnerships, AC Energy will maximize its market reach by delivering a commodity of peerless value with virtually unlimited applications in commercial, industrial and military markets.
Forward-Looking Statements:
Note: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation, and the other risk factors listed from time to time in reports filed by AC Energy Corp. with the Securities and Exchange Commission, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operation and Our Stock Price." The forward-looking statements contained in this news release represent judgments of the management of AC Energy Corp. as of the date of this release. AC Energy Corp. and its managers and agents undertake no obligation to publicly update any forward-looking statements.
CONTACT:
AC Energy Inc.
775-782-6739
1528 Hwy 395 N #130
Gardnerville, NV 89410
PHGI - Perihelion Global Provides Update on OTC:BB Shell Acquisition; Announces Management Change
Jun 1, 2007 10:23:00 AM
WILMINGTON, DE and SANTA ROSA BEACH, FL -- (MARKET WIRE) -- 06/01/07 -- Perihelion Global (PINKSHEETS: PHGI), a development company with interests in natural resources, alternative energies, and advanced communications, today provided an update on the previously disclosed transaction to list its common shares on the OTC:BB by virtue of acquiring a fully reporting public shell company.
For the last month, the company has contacted and has been contacted by several interested parties to the proposed transaction. Although Perihelion believes that it has established discussions with credible and 'clean' shell corporations, management stresses that it is essential the process be thorough and it leaves 'no stone unturned' in regards to due diligence required to consummate the transaction.
Perihelion Global Chairman, Chief Executive Officer, and President, John H. Beebe, commented, "We're just as anxious as many of our shareholders are to complete a change of venue to the bulletin board, however we must make the move forward in a fashion that benefits our corporation and its shareholders to the fullest extent. We're looking for very specific profiles -- shells that have extremely limited operating, trading, along with clearly defined ownership history -- essentially, as much 'shrink wrap' as possible. At present, there are two opportunities we believe meet our criteria that we are intensively exploring and conducting Due Diligence on. We believe taking a more methodical approach will extend considerable long-term security to our corporation from recent lessons learned, and we continue to appreciate the patience of our shareholders during the process."
The company also announced that it has accepted the resignation of Dr. Patrick LaRive as Vice President of the corporation. Perihelion wishes Dr. LaRive the best in his future endeavors, and appreciates his prior service to the company.
About Perihelion Global:
Perihelion Global focuses on the acquisition, development and management of technologies, strategic commodity reserves and assets in the energy, natural resource and communications markets. Perihelion's management team specializes in providing solutions for the strategic challenges of the 21st Century. We lead with decades of experience in environments that are mission critical in today's global marketplace: Technology, Energy and Communications.
Website: http://www.perihelion.com
Caution Regarding Forward-Looking Statements
This press release contains historical information as well as forward-looking statements that are based upon our estimates and anticipation of future events that are subject to certain risks and uncertainties that could cause actual results to vary materially from the expected results described in the forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "hopeful," "intend," "may," "optimistic," "preliminary," "project," "should," "will," and similar expressions are intended to identify these forward-looking statements. There are numerous important factors that could cause our actual results to differ materially from those in the forward-looking statements. Thus, sentences and phrases that we use to convey our view of future events and trends are expressly designated as Forward-Looking Statements as are sections of this news release clearly identified as giving our outlook on future business.
These forward-looking statements are subject to significant risks, assumptions and uncertainties, including, among other things, the following important factors that could affect the actual outcome of future events:
-- General economic conditions, either nationally or in our market area, that are worse than expected;
-- regulatory and legislative actions or decisions that adversely affect our business plans or operations;
-- price competition;
-- inflation and changes in the securities markets that adversely affect the fair value of our operations; and
-- changes in our organization, compensation and benefit plans.
We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made, and wish to advise readers that the factors listed above could affect our financial performance and could cause actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. We do not undertake and specifically decline any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
Contact:
John H. Beebe
Chairman, Chief Executive Officer & President
Perihelion Global
866-748-7610 (Toll Free) x 719
john@perihelion.com
SGMG - Spectre Gaming Signs Definitive Agreement With Chase Berkshire for the Lease/Purchase of 180 AWP Devices
Jun 1, 2007 9:55:00 AM
MINNEAPOLIS, June 1 /PRNewswire-FirstCall/ -- Spectre Gaming, Inc. (OTC Bulletin Board: SGMG) announced today that it has entered into a capital lease transaction with Chase Berkshire Holdings LLC for the lease/purchase of 180 of the Company's AWP devices for use in Alabama. The agreement is valued at $1.26 million.
D. Bradly Olah, CEO of Spectre stated, "We are pleased to have executed this agreement. Proceeds from the transaction will be applied to outstanding debt to PDS Gaming Corporation, the Company's largest lender. PDS has loaned the Company in excess of $5,000,000 for the purchase of equipment and licenses, and continues to be a supportive partner. With the lease/sale of this equipment, Spectre can transition at a faster pace to its new Titan platform as well as reduce debt."
About Spectre Gaming
Spectre Gaming, Inc. is a provider of proprietary interactive electronic games to the amusement-with-prize (AWP) and charitable gaming markets. The Company designs and develops networks, software and content that provide its customers with a comprehensive gaming system. Learn more at http://www.spectregaming.com .
Risk Factors and Forward-Looking Statements
This news release contains various "forward-looking statements" which are not historical in nature, including but not limited to statements using the terms "may," "expect to," "believe," "should," "anticipate," and other language using a future aspect. Such statements should be viewed as uncertain and should not be relied upon. Although our management believes that the results reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the expectations expressed in such forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include those set forth in the Company's annual report on Form 10-KSB for the year ended December 31, 2006 and in other filings made, from time to time, by the Company with the Securities and Exchange Commission, including the Company's quarterly report filed on May 30, 2007. The forward-looking statements contained herein speak only as of the date when made and the Company does not undertake to update such statements.
SOURCE Spectre Gaming, Inc.
----------------------------------------------
D. Bradly Olah
CEO of Spectre Gaming
+1-612-281-5000
NVAX - Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show
Study Presented at Second International Conference on Avian Influenza at France's Pasteur Institute
Jun 1, 2007 8:30:00 AM
PARIS, June 1 /PRNewswire-FirstCall/ -- Very low doses of Novavax Inc.'s pandemic influenza vaccine provided protection against a lethal challenge of live H5N1 viruses, according to pre-clinical data presented here today at the Second International Conference on Avian Influenza in Humans.
The data show that two 0.6 microgram doses of Novavax's virus-like particle (VLP) H5N1 vaccine -- without the addition of an adjuvant -- protected ferrets from challenges with live H5N1 bird flu viruses. This dose is 25 fold lower than the average human dose for most seasonal flu vaccines and more than 100 times lower than other H5N1 vaccines against avian influenza. Novavax plans to submit an investigational new drug application to the U.S. Food and Drug Administration in mid-2007 to commence human clinical trials with the novel H5N1 influenza vaccine.
"We are extremely encouraged that even very low doses of our vaccine are proving to be effective in pre-clinical models without the need for adjuvants," said Dr. Rick Bright, Novavax's Vice President of Global Influenza Programs. "This may be important in a pandemic, where the vaccine supply could possibly need to be 'stretched' to meet the significant global demand."
In the study, ferrets were inoculated with a range of doses of the company's VLP vaccine made from an Indonesian strain of H5N1 avian influenza. The ferrets, which represent the most relevant influenza animal model for humans, were then challenged with live H5N1 virus, and all survived. The typical human dose of a seasonal influenza vaccine is 15 micrograms. Other pandemic vaccines with no adjuvant have shown only modest levels of immunogenicity in humans with doses as high as 90 micrograms. In this study, ferrets received either 15, 3 or 0.6 micrograms of Novavax's vaccine, and all immunized animals had similar survival results.
In addition, ferrets were protected not only against the Indonesian strain of avian flu but were cross-protected against a separate challenge strain originating in Vietnam. Again, all ferrets that received the Novavax vaccine survived, even those that received the lowest 0.6 microgram dose.
The International Conference on Avian Influenza in Humans brings together leading bird flu experts at the Pasteur Institute to review and discuss the latest scientific advances in vaccine prevention strategies and treatments designed to stem a pandemic.
The U.S. Centers for Disease Control and Prevention currently is testing antibodies from these animals against a number of additional strains of H5N1 that have been detected in recent years to establish whether the vaccine is even more broadly cross-protective.
"We are eager to begin our human clinical trials so that we can continue to evaluate the immunogenicity of our vaccine," Dr. Bright said. "The goal of prevention in a pandemic setting is to be prepared with a vaccine that can protect against varying strains of the virus that mutate as they travel around the globe, and to have enough supply to protect vulnerable populations. We believe our VLP vaccine may provide a unique solution to this potential public health threat."
VLPs mimic the three-dimensional structure of a virus but do not contain genetic material, so they cannot replicate or cause infection. As VLPs maintain functional properties of both influenza surface proteins (hemagglutinin and neuraminidase), they have been shown to activate multiple arms of the immune system to generate a broadly protective immune response.
"We continue to learn more about the potency of our VLP based flu vaccines, which have been shown to induce broadly reactive antibodies, provide efficacy against drifted flu strains, and elicit both B cell and T cell responses," Dr. Bright said. "This information is being used to design clinical studies that have the potential to demonstrate the advantages of the VLP flu vaccines in humans."
About Novavax Inc.
Novavax Inc. (Nasdaq: NVAX) is committed to leading the global fight against infectious disease by creating novel, highly potent vaccines that are safer and more effective than current preventive options. Using the company's proprietary virus-like particle (VLP) and Novasome(R) adjuvant technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax's particulate vaccines closely match disease-causing viruses while lacking the genetic material to cause disease, which provides potential for greater immune protection at lower doses than current vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of vaccines, Novavax is uniquely positioned to meet global public health needs.
Forward-Looking Statements
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical developments, safety, efficacy and potency of our vaccines, and supply availability are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by Novavax to secure and maintain relationships with collaborators; risks relating to the early stage of Novavax's product candidates under development; uncertainties relating to commencing clinical trials and their outcome; risks relating to the supply and commercialization, if any, of Novavax's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward- looking statements.
SOURCE Novavax Inc.
----------------------------------------------
Mariann Caprino of Novavax Inc.
+1-240-268-2029
Scalp CALP? (lol) Caliper Life Sciences Receives Significant Patent on Key Biophotonic Imaging Technology
- New Patent Covers Important Classes of Fluorescent and Bioluminescent In Vivo Imaging Methods -
May 31, 2007 8:46:00 AM
HOPKINTON, Mass., May 31 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced its receipt of the Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent covering key methods of in vivo, non-invasive (in living animals, through opaque tissue) imaging of light generated from within mammals. Biophotonic imaging, one of the fastest growing technologies in the life sciences, is rapidly expanding beyond current methods based on light sources genetically encoded in mammals to also include methods based on light sources that are conjugated (or combined) with a biocompatible entity and administered to mammals. Caliper's newly allowed patent covers many of these important developments in biophotonic imaging science.
"In addition to providing researchers with the option to track disease states in an animal without requiring genetic modification of the animal to produce light, the methods covered by the new patent, which encompass a broad range of biophotonic imaging with conjugated probes, are particularly attractive for translation of pre-clinical applications and results into clinical settings," said Kevin Hrusovsky, chief executive officer of Caliper Life Sciences. Mr. Hrusovsky added, "This patent furthers Caliper's leadership position in the biophotonic imaging market. We intend to augment our considerable technology development efforts by also developing biomarkers and innovative conjugate imaging probes and applications for our customers using the technology covered by the patent."
Caliper's existing patent portfolio covers broad methods of in vivo imaging of genetically-produced light generation. The new patent covers the use of conjugates comprising any biocompatible entity and a light source, either fluorescent or bioluminescent. The biocompatible entity can be a cell, microorganism, particle or biological molecule, such as a protein, peptide, or antibody. The data produced from such non-invasive imaging provides researchers with unprecedented insight into events occurring at a molecular level and enables drug developers to gain specific knowledge about potential drug compounds earlier in the drug development process, thus potentially reducing the time to market.
"Caliper's ability to provide license rights to the imaging methods covered by this new patent should further motivate end-users to acquire not only licensing rights but also imaging systems from Caliper. In addition, we believe this new patent will enable us to expand our existing licensing program to a larger group of companies, some of which are already performing non-invasive in vivo imaging with other manufacturers' imaging equipment," said Mr. Hrusovsky, adding that, "We believe revenues from additional imaging products and licenses will begin to materialize in the back end of this year and we are reaffirming our full year revenue guidance of $137 - $143 million which reflects second half pro forma revenue growth of 14% - 23% and GAAP revenue growth of 24% - 34%."
Caliper's family of Xenogen IVIS(R) imaging platforms provides scientists with innovative biophotonic imaging technologies. The IVIS systems deliver real-time in vivo imaging along with high sensitivity, ease of use and exceptional data quality. Caliper has placed over 400 units to date and has recently launched the new Xenogen IVIS Spectrum system to provide state-of-the-art bioluminescence and fluorescence capabilities in a single unit.
The Notice of Allowance corresponds to U.S. patent application serial number 11/143,422 entitled "Non-invasive localization of a light-emitting conjugate in a mammal." A U.S. patent corresponding to the Notice of Allowance will issue when the USPTO receives the requisite issuance fee.
About Caliper Life Sciences
Caliper Life Sciences is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. With its acquisitions of NovaScreen Biosciences and Xenogen Corporation, Caliper has positioned itself to transform drug discovery and development through a keen focus on clinically relevant experimentation. Caliper's products and services, assembled from a leading portfolio of microfluidics, liquid handling, and imaging technologies, span in vitro and in vivo experimentation and address key issues on the critical path of drug discovery and development. More information about Caliper can be found at http://www.caliperLS.com.
The statements in this press release regarding future events, including statements regarding Caliper's plans to develop imaging probes, biomarkers and applications, Caliper's ability to expand its imaging licensing program based on the allowance of this new patent, and Caliper's belief that its newly allowed patent will have a positive impact on its revenue in 2008 and beyond, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statement as a result of a number of factors, including the risk that unexpected difficulties may be encountered in developing new imaging probes, biomarkers and applications or in obtaining new license agreements with companies already performing biophotonic imaging. Further information on risks faced by Caliper with respect to its microfluidic technology are detailed under the caption "Risks Related To Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2006. This filing is available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release.
Caliper, IVIS, NovaScreen and Xenogen are registered trademarks, and Spectrum is a trademark, of Caliper Life Sciences, Inc.
SOURCE Caliper Life Sciences, Inc.
----------------------------------------------
Tom Higgins
Chief Financial Officer of Caliper
+1-508-497-2809; or Stacey Holifield of Schwartz Communications for Caliper
+1-781-684-0770
caliper@schwartz-pr.com